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CHAPTER I 
 
 
 
OVERVIEW 
 
 
 
 Since the discovery of p53, more than 30 years of research has yielded 
numerous publications all aiming to better understand p53 signaling in normal 
and disease states.  First discovered as a proto-oncogene, p53 has since been 
shown to act as a potent tumor suppressor through both transcription-dependent 
and –independent signaling mechanisms.  The goal of my dissertation research 
was to perform genomic analyses that would identify a subset of novel p53 target 
genes and further elucidate their functional roles downstream of the p53 signaling 
network. 
 
Introduction 
  Prior to the invention of genomic technologies, the identification of 
putative transcriptional targets consisted of a gene-by-gene approach using 
nuclease protection assays as well as in vitro DNA binding and reporter assays.  
As a result, identification of transcription factor signaling networks was 
challenging.  The advent of genomic analyses such as gene expression 
microarrays, genome-wide chromatin immunoprecipitation (ChIP) methods, and 
novel computational algorithms has allowed for the high-throughput discovery of 
transcriptional networks.  There are approximately 2600 proteins in the human 
  2 
genome that are assumed to function as transcription factors based on 
identification of DNA binding domains (Sturzbecher et al., 1992).  As these 
genomic methods allow further identification of transcriptional targets for the 
numerous potential transcription factors, we are beginning to understand the vast 
signaling capability that a single transcription factor has, both uniquely and 
through crosstalk with other transcription factors and co-factors.  Further, these 
signaling networks will likely have important clinical utility, given that sequence 
mutations in transcription factors are the cause of multiple disease states and 
can be exploited as potential therapeutic targets.  
A sequence-specific transcription factor contains a DNA binding domain 
that recognizes a unique genomic sequence and may bind to thousands of 
locations in the genome.  A variety of factors influence the activity of transcription 
factors including spatial localization, accessibility of the DNA-binding site, and 
sequence specific recognition of the consensus binding region (Mitchell and 
Tjian, 1989).  Cellular localization itself is often regulated by protein-protein 
interactions or post-translational modifications.  Protein interactions and post-
translational modifications may activate a transcription factor by targeting it to the 
nucleus or alternatively inactivate the transcription factor by marking it for 
degradation (Ptashne and Gann, 1998).  For example NF-kappaB is maintained 
in the cytoplasm due to a protein interaction with Inhibitor kappaB alpha by 
obscuring the nuclear import signal (Baeuerle and Baltimore, 1988).  In addition, 
numerous stress events, such as DNA damage, can influence protein-protein 
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interactions and post-translational modification of a transcription factor to regulate 
its subcellular localization and, ultimately, its activity (Cheng et al., 2009; 
Rathmell et al., 1997).   
 In addition to localization, a transcription factor and the basal transcription 
machinery require accessibility to the DNA binding region.  Chromatin is made up 
of DNA wrapped around histone proteins (nucleosomes) and can be found either 
condensed as heterochromatin or during interphase in a loose state known as 
euchromatin (Olins and Olins, 1974).  Chromatin structure due to nucleosome 
placement can also create DNA-specific binding sequences from two half-sites 
that are not close in the coding region but by bringing the DNA loops together the 
two halves of a DNA binding sequence can achieve close spatial orientation 
(Rippe et al., 1995).  
 For precise regulation of gene expression, another tier of specificity is 
observed at the genome level using the consensus binding site.  Consensus 
sequences, also referred to as response elements, are commonly located in the 
promoter region, enhancer, or within one kB downstream of the transcriptional 
start site of a gene.  A response element contains a unique sequence of DNA 
that can be specifically recognized by a transcription factor.  The complexity of 
response element binding by transcription factors is augmented by the fact that 
response elements can be degenerate, variations of the consensus binding 
sequence that can confer different binding affinities.  The p53 consensus binding 
site consists of two 10 bp half-sites (5ʼ-PuPuPuC(A/T)(T/A)GPyPyPy-3ʼ, where 
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Pu=Purine and Py=Pyrimidine) separated by a 0-13 spacer (el-Deiry et al., 1992).  
Since the initial definition of the consensus binding site, genomic screening has 
shown that the 20 bp palindrome without a spacer is preferentially bound by p53 
tetramers (Ma and Levine, 2007; Wei et al., 2006). 
 
p53: Sequence-Specific Transcriptional Activator and Tumor Suppressor 
 p53 was first discovered in 1979 and described as a proto-oncogene 
(Lane and Crawford, 1979; Linzer and Levine, 1979).  After three decades of 
work and greater than 53,000 published articles, we now understand this 
transcription factor is a potent tumor suppressor (Hinds et al., 1989; Levine, 
1989).  One observation linking p53 to tumor suppressor activity was that ectopic 
wild-type p53 expression inhibited oncogene-mediated rat fibroblast 
transformation and colony forming ability (Eliyahu et al., 1989).  Moreover, rare 
clones that did undergo transformation in those studies expressed a mutant, 
inactive form of p53 (Finlay et al., 1989).  Another key observation defining p53 
as a tumor suppressor was allelic deletions of the p53 locus on chr 17 in 75% of 
colon cancers, and the remaining p53 allele showed mutated p53 in two tumors 
studied resulting in the classic Knudson two-hit hypothesis for a tumor 
suppressor gene (Baker et al., 1989; Knudson, 1971).  
Since its discovery, studies have characterized p53 as the most frequently 
mutated gene in all human tumors (Caron de Fromentel and Soussi, 1992; 
Hollstein et al.).  In 2009, the International Agency for Research on Cancer 
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counted 26,597 published somatic mutations and 535 germline mutations in the 
p53 gene (Petitjean et al., 2007).  Of these somatic mutations, the majority are 
comprised of missense mutations located in the DNA binding domain that alter 
the ability of p53 to bind to DNA (Flaman et al., 1998).  As point mutations in p53 
continue to be studied, there is growing evidence that these alterations not only 
inhibit p53 binding to its consensus sites but also confer dominant-negative 
activity through dimerization of the mutant and wild-type p53 (Milner and Medcalf, 
1991).  
Germline p53 mutations are not infrequent, and genomic sequencing in 
larger patient populations suggest that alterations in p53 may be responsible for 
as much as 20% of all inherited cancers (Palmero et al. 2010).  Li-Fraumeni 
syndrome is an autosomal dominant disorder most commonly associated with a 
germline mutation in p53 (Malkin et al., 1990), but has also been attributed to 
mutations in CHK2 (Bell et al., 1999).  Patients with Li-Fraumeni are at risk for 
early onset of a wide range of cancer types including breast, brain, soft tissue 
sarcomas, bone sarcomas, and adrenal cortical carcinomas (Bell et al., 1999; 
Birch et al., 2001; Malkin et al., 1990). 
In tumors where mutations in p53 are not present, there are frequent 
alterations in other nodes of the p53 signaling pathway.  For example, the 90 kDa 
protein murine double mutant 2 (MDM2) binds and negatively regulates p53 
(Momand et al., 2000), and is amplified in numerous cancers that retain wild-type 
p53 (Fakharzadeh et al., 1991).  In neuroblastoma tumors that rarely exhibit 
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mutations of p53, homozygous deletion of p14ARF allows escape from p53-
mediated growth arrest (Thompson et al., 2001).  p14ARF in normal conditions 
serves to sequester MDM2 thus inhibiting the E3 ubiquitin ligase activity of 
MDM2 to degrade p53 (Honda and Yasuda, 1999).  
Due to its ability to induce growth arrest and apoptosis in a majority of 
tumor types, p53 is commonly considered an anticancer therapeutic target.  p53 
is a challenging target, as it is frequently lost or mutated in human tumors.  
Therefore therapeutic approaches include activating wild-type p53, reactivating 
and selectively inhibiting mutant p53, or selectively inhibiting the wild-type p53 in 
normal cells to reduce side-effects during chemoradiation.   
Currently several adenoviral vectors carrying wild-type p53 that require 
intratumoral injection (brand name Advexin) are in clinical trials and are being 
well tolerated and efficacious in late stage disease patients (Vazquez et al., 
2008).  Another adenoviral vector, ONYX-015, selectively replicated in p53-
deficient cancer cells (Bischoff et al., 1996).  Although only minor antitumor 
activity was seen with ONYX-015 alone, a significant antitumor effect was 
achieved when combined with chemotherapeutic agents (Heise et al., 2000; 
Khuri et al., 2000).   
In addition to gene therapy, other approaches for modulation of p53 
activity are being developed, including investigation of small molecules that either 
directly interact with p53 or disrupt normal interactions with negative regulators 
such as MDM2.  For example, Nutlins are a class of small-molecule MDM2 
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inhibitors that have antitumor efficacy in mouse xenograft models (Vassilev et al., 
2004).  Nutlin binds MDM2 at the p53-binding pocket, inhibiting the MDM2-p53 
interaction and stabilizing p53.  Additionally, RITA (reactivation of p53 and 
induction of apoptosis) was identified in a chemical screen of small molecules 
designed to bind to p53 and block its interaction with negative regulatory factors.  
In mouse models, RITA induced tumor cell apoptosis under conditions of 
normoxia and hypoxia (Issaeva et al., 2004; Yang et al., 2009).     
 
p53 Structure and Regulation 
p53 is a 393 amino acid (aa) protein containing an N-terminal 
transcriptional activation domain (1 - 63 aa), a proline rich domain (64 - 92 aa), a 
central DNA binding domain (93 - 300), a nuclear localization signal domain (316- 
325 aa), a homo-oligomerization domain (307 - 355 aa), and a C-terminal domain 
that is involved in regulation of the DNA binding domain (356 - 393aa) (Cho et al., 
1994; Muller-Tiemann et al., 1998; Wang et al., 1994) (Figure 1a).  Each domain 
is crucial for the regulation and transcriptional activity of p53.  As its name 
suggests, the N-terminal transcriptional activation domain is the binding region 
for cofactors that regulate the transcriptional activity of p53, such as MDM2. 
(Fields and Jang, 1990; Momand et al., 1992).  The proline-rich domain is 
thought to be necessary for the pro-apoptotic function of p53.  Specifically,  
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binding of the apoptotic specific regulator of p53 (ASPP) family of proteins occurs 
in this proline rich domain, and this cofactor interaction has been reported to 
influence the ability of p53 to induce a subset of pro-apoptotic target genes 
(Samuels-Lev et al., 2001).  Additionally, p53 proteins lacking the proline-rich 
domain fail to activate specific target genes such as PIG3 and as a result are 
unable to induce apoptosis (Baptiste et al., 2002 1998, Bergamaschi et al, 2006).   
The DNA binding domain is comprised of an antiparellel β sandwich that is 
stabilized by a Zn++ ion to enable interaction with, and binding of, DNA (Duan and 
Nilsson, 2006; Pavletich et al., 1993).  Mutations occurring in the DNA domain 
may disrupt protein structure and alter the ability of p53 to bind DNA (Cho et al., 
1994).  The oligomerization domain contains an amphipathic helix that allows for 
homodimerization and formation of transcriptionally active p53 tetramers 
(Sturzbecher et al., 1992 1994).  Lastly, post-translational modifications such as 
phosphorylation, glycosylation, ubiquitination, acetylation, and sumoylation occur 
frequently in both the N- and C-terminal region of p53.  The C-terminal domain 
can negatively regulate p53 activity through its non-specific nucleic acid binding 
activity (Bayle et al., 1995).   Modifications at the C-terminus often inhibit the 
ability of this domain to negatively regulate sequence-specific DNA binding of 
p53 (Weinberg et al., 2004).  Additionally, these modifications can alter protein 
stability (Li et al., 2003a), oligomerization state (Nicholls et al., 2002), nuclear 
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export (Stommel et al., 1999), and degree of ubiquitination of p53 (Nakamura et 
al., 2000; Rodriguez et al., 2000). 
 p53 stability is regulated at the protein level by post-translational 
modifications that either stabilize or mark the protein for degradation.  MDM2 is a 
proto-oncogene that functions as a major negative regulator of p53 (Momand et 
al., 2000).  MDM2 is a transcriptional target of p53; this regulation creates an 
auto-regulatory feedback loop that acts to tightly regulate p53 activity.  Upon 
stabilization, p53 transcriptionally induces expression of MDM2 that, in turn, 
functions as an E3 ubiquitin ligase to target p53 for nuclear export and 
proteasomal degradation (Honda et al., 1997).  The p53 nuclear export signal 
(NES) is structurally masked in its tetrameric complex.  p53 ubiquitination by 
MDM2 disrupts the tetrameric state of p53 and exposes its NES, at which point 
p53 is translocated to the cytoplasm for degradation (Freedman et al., 1997).  
Depending on tissue- or stress–specific contexts, p53 forms autoregulatory loops 
with other E3 ubiquitin ligases (Pirh2, COP1) (Dornan et al., 2004; Leng et al., 
2003) and ubiquitin analogues (SUMO1, Nedd8) (Buschmann et al., 2000 2004).   
 In addition, post-translational modifications of p53 occur at more than 40 
different amino acid residues, where they act to influence p53 stability, 
localization, and co-factor interactions.  These regulating modifications include, 
but are not limited to, acetylation by pCAF and p300 (Liu et al., 1999), 
phosphorylation by ATM, ATR, and CK2 (Gu and Roeder, 1997; Jongmans et al., 
1996) and sumolation through PML nuclear bodies (Buschmann et al., 2001).  
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One well-characterized event is the phosphorylation of p53 at serine-15 (S15) by 
DNA-protein kinase (Lees-Miller et al., 1992).  p53 S15 mutations abrogate the 
ability of p53 to induce cell cycle arrest.  Microtubule-inhibitors increase 
phosphorylation at S15 and threonine-18 (T18) (Stewart et al., 2001).  Moreover 
phosphorylation of serine-46 (S46) is important for transcriptional induction of 
pro-apoptotic genes by p53 (Oda et al., 2000b).  Although much emphasis is 
placed on deciphering the “code” of p53 post-translational modifications and cell 
fate determination, the in vivo importance of these modifications in disease is still 
unclear.  As mentioned above, the majority of missense mutations in human 
tumors occur in the DNA-binding domain and inhibit the ability of p53 to bind and 
transcriptionally activate its target genes.  These hotspot mutations do not 
commonly coincide with amino acids that are post-translationally modified in p53, 
and the N- and C-terminal domains that are locations of modification are 
infrequently altered in tumors.  
 
The p53 Family of Transcription Factors 
 Although the discovery of p53 preceded that of its family members, p63 
and p73, p53 is evolutionarily the youngest of the family (Yang et al., 1998 1997).  
Invertebrate species express a single p63-like protein, and the existence of all 
three family members did not occur until the evolution of vertebrate species 
(Derry et al., 2001).  While the three family members exhibit significant sequence 
and structural homology, they retain both overlapping and unique functions.  
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Each family member gene encodes an N-terminal transactivation domain, a 
central DNA binding domain, and C-terminal oligomerization domain (Figure 1b).  
Despite the common gene structures, p63 and p73 can exist as one of a number 
of protein isoforms resulting from usage of multiple transcriptional start sites (TA 
and ∆N), as well as numerous C-terminal splicing events.  To date, at least six 
different p63 isoforms and 14 (of 35 theoretical) p73 isoform variants have been 
described (De Laurenzi et al., 1998; Stiewe et al., 2002; Yang et al., 1998).  Until 
recently, p53 was thought to exist as a single isoform, but recent studies suggest 
as many as nine possible p53 variants (Ghosh et al., 2004).  In addition to 
common protein regions within the family, p63 and p73 contain a C-terminal SAM 
domain that mediates protein-protein interactions (Figure 1b).  The functional 
significance of the p63 SAM region became evident with the discovery that 
germline mutations in this domain result in developmental disorders such as 
ectodermal dysplasia and limb-mammary syndrome (Brunner et al., 2002). 
 Unlike p53-/- mice that develop normally and succumb to spontaneous 
tumorigenesis (Donehower et al., 1992), p63-deficient mice die shortly following 
birth due to the complete lack of stratified epithelia and all its derivatives (Mills et 
al., 1999; Yang et al., 1999).  These murine phenotypes are recapitulated in 
human disease, as heterozygous germline p63 mutations result in ectodermal 
dysplasia, orofacial clefting, and limb malformation (Celli et al., 1999; Ianakiev et 
al., 2000; Perez et al., 2007). 
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 Global deletion of the p73 gene in mice results in neurological, 
immunological, and pheromonal defects, evidence that p73, like its family 
member p63, is required for a number of developmental processes (Yang et al., 
2000).  Recently, the studies of mouse models with isoform specific p73 deletions 
have shown that p73 regulation of distinct biological processes must be studied 
in the context of individual isoforms. The first isoform specific knockout generated 
was TAp73-/- mice (Tomasini et al., 2008).  These mice were similar to the p73-/- 
mice, in that they exhibited infertility and hippocampal dysgenesis.  Unlike global 
p73-deficient mice, 73% of TAp73-/- mice died from the development of 
spontaneous tumors, most of which were comprised of lung adenocarcinomas.  
Global deletion of the ∆Np73 isoform resulted in mice that were fertile, yet 
displayed signs of neurodegeneration.  Evidence also showed that ∆Np73 
depletion resulted in an increased sensitivity to DNA damage, along with higher 
levels of p53-dependent apoptosis (Wilhelm et al, 2010). 
 As homozygous p63 deletions are incompatible with life, heterozygous 
mouse studies also suggest a role for p63 in tumor suppression, where 10% of 
p63+/- mice developed squamous cell carcinomas.  These studies suggest that 
loss of a single p63 allele is sufficient for the development of tumors (Flores et 
al., 2005).  Additionally, compound heterozygote p53+/-p63+/- mice displayed a 
striking difference in the rate of tumor metastasis compared to p53+/- supporting a 
role for p63 not only in tumor suppression but also in metastasis.  Interestingly, 
p63 is rarely mutated in human tumors and is most often overexpressed in 
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squamous cell carcinomas, suggesting an oncogenic function of p63 in 
tumorigenesis (Sniezek et al., 2004; Yamaguchi et al., 2000).  Like squamous 
cell carcinomas, a subset of breast cancers display a basal-like phenotype 
overexpressing ΔNp63α, consistent with numerous reports that this isoform can 
act in a dominant-negative manner towards the pro-apoptotic functions of its 
family members, p53 and p73 (Perou et al., 2000; Yang et al., 1998).  
Despite their unique differences with regards to signaling, the p53 family 
members retain the ability to functionally cooperate, as evidenced by their ability 
to physically interact with each other.  p73 and p63 can form homotetramers, as 
well as heterotypic interactions amongst themselves but not with wild-type p53 
(Davison et al., 1999).  Mutated p53 is suggested to function in a dominant 
negative fashion by interacting with wild-type p53 and inhibiting its activity 
through the p53 oligomerization domain.  Similarly, interactions between the core 
domain of mutant p53 and p73 can downregulate the growth suppressive pro-
apoptotic anti-tumoral activity of p73 isoforms (Gaiddon et al., 2001; Strano et al., 
2002).  
With approximately 60% sequence identity in the DNA binding domain, the 
p53 family of transcription factors have both overlapping and unique binding 
motifs (Osada et al., 2005; Perez et al., 2007; Yang et al., 2006).  For example, 
selectivity in target gene expression can occur due to the preference of p63 for 
A/G at position 5 and C/T at position 16 in the consensus binding sequence 
(Perez et al., 2007).  ChIP analysis following ectopic expression of individual p53 
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family members showed that 72% of the p53-binding sites could be bound by p63 
and/or p73 (Smeenk et al., 2008).  Work presented in Chapter III of this 
dissertation will describe subsets of genes both uniquely regulated by p53, as 
well as genes co-regulated by different p53 family members.   
p53 family members can also functionally cooperate to regulate specific 
biological outcomes, such as apoptosis.  p63-/-  p73-/- MEFs are unable to 
undergo p53-dependent apoptosis after DNA damage, suggesting the necessity 
of p63 and p73 as co-factors during p53-dependent apoptosis (Flores et al., 
2002).  In addition to cooperative protein interactions at select promoters, p53, 
p63, and p73 participate in cross-family feedback loops.  For example, ∆Np73 
expression is regulated by p53 to form a negative autoregulatory loop, whereby 
∆Np73 competes at p53 consensus binding regions (Kartasheva et al., 2002).  
Additionally, p73 activation after DNA damage induces MDM2, a negative 
regulator of both p53 and p73 activity (Wang et al., 2001).  MDM2 binds and 
sequesters p73, negatively regulating its transcriptional activity by inhibiting the 
ability of p73 to interact with its coactivator, p300 (Zeng et al., 1999). 
 
Methods for the Identification of Transcriptional Target Genes 
Initially, the discovery of transcription factor target genes primarily 
occurred through a one-assay-one-gene approach, thus limiting the ability to 
rapidly discover large signaling networks regulated by a single transcription 
factor.  Given the human genome consists of four unique DNA bases, a six bp 
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response element is predicted to occur >700,000 times in the genome (Georges 
et al.).  With the release of the human genome sequence, algorithms using 
position weight matrices (PWM) were created to predict in silico transcription 
factor binding sites (Venter et al., 2001).  Though useful, in silico methods are 
unable to assess chromatin structure or account for the necessary activation of 
transcription factors, thus yielding numerous false positives.   
While in silico methods often fail to address in vivo issues, chromatin 
immunoprecipitation (ChIP) methods enable the identification of response 
elements directly bound by a transcription factor under a given biological 
condition.  It is important to note that this method identifies DNA binding sites and 
putative transcriptional targets in the biologically-relevant context of normal or cell 
stress conditions, as well as the state of chromatin structure.  ChIP-sequencing 
(ChIP-seq) allows for the high-throughput identification of genomic transcription 
factor binding sites (Johnson et al., 2007).  ChIP-seq does not require large 
amounts of starting material and the sequencing platforms allow greater 
coverage than can be achieved with ChIP-library methods.  Of course this 
method also has limitations including antibody availability, epitope access,  and 
specificity for use in the immunoprecipitation step.  Moreover, CHIP relies on 
chemical crosslinking that may unnecessarily include interactions of extraneous 
DNA-protein or protein-protein bonds.  Lastly, the necessary starting material to 
perform large-scale ChIP assays is often prohibitive in primary cultures or clinical 
specimens (Kang et al., 2002).   
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ChIP-based methodologies are useful tools to identify putative regulatory 
sites for a transcription factor; however, it does not yield data about regulation of 
a gene near the bound response element.  To address the latter, an investigator 
can combine ChIP analysis with gene expression microarray technologies to 
correlate binding and regulation of a gene.  Microarray experiments allow for 
analysis of gene expression under control and experimental conditions, one of 
which could be used to study transcription factors (Schena et al., 1995).  Gene 
expression microarrays allows comprehensive analyses of transcript level 
changes across samples but does not inform whether changes in gene 
expression are a direct result of the condition you are testing or rather a by-
product of secondary signaling.  The work presented in Chapter III of this thesis 
is based on the integrated analysis of multiple genome-wide ChIP and gene 
expression microarray analyses for the identification of direct p53 target genes. 
 
 
Transcription-Dependent Functions of p53 
 Currently, 150 genes have been published and functionally characterized 
as p53 transcriptional targets.   Genome-wide ChIP analyses have revealed that 
p53 has approximately 1600 binding sites in the genome (Cawley et al., 2004; 
Smeenk et al., 2008).  Perhaps the most well-known transcription-dependent 
functions of p53 include transcriptional activation of target genes involved in cell 
cycle regulation, genomic stability, cellular senescence, and apoptosis with 
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growing evidence for target genes involved in angiogenesis, cell migration, and 
autophagy. 
 
Role of p53 in Cell Cycle and Genomic Stability 
p53 transcriptional activity is essential for proper G1 cell cycle checkpoint 
function (Pietenpol et al., 1994).  The first p53 target gene described was p21 
(CDKN1a/WAF1/CIP1) (el-Deiry et al., 1993).  p21 is a cyclin-dependent kinase 
inhibitor that binds to and inactivates cyclin-CDK2 and –CDK4 complexes that 
are necessary for progression through the G1-phase of the cell cycle (Gu et al., 
1993).  p21 is necessary for DNA damage induced, p53-dependent, G1 arrest 
(el-Deiry et al., 1994).  While p53 is most well-known for its ability to induce target 
gene expression, it also retains transcriptional repressor activity.  Repression of 
c-Myc expression by p53 is necessary for G1-phase cell cycle arrest to occur (Ho 
et al., 2005; Sachdeva et al., 2009).  This repression occurs through a 
mechanism of histone deacetylation, as well as through induction of miR-145 by 
p53 that itself downregulates c-Myc.   
 Entry into mitosis can also be blocked by p53 after DNA damage at the 
G2/M checkpoint, and this arrest is mediated by a number of genes and different 
mechanisms.  One mechanism of p53-mediated G2/M arrest is through the 
inhibition of CDK1/cyclinB complexes by p21 (Harper et al., 1995; Medema et al., 
1998). The growth arrest and DNA damage inducible gene 45 (GADD45) is 
another p53 transcriptional target that causes the G2/M arrest by dissociating the 
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cyclin B subunit from CDK1 (Zhan et al., 1999).  Our group showed that p53 
prevents premature exit from G2 cell cycle arrest through a p21 and RB-
dependent mechanism that inhibits and then decreases cyclin B1-CDK1 activity 
(Flatt et al., 2000).  p53 also transcriptionally activates 14-3-3σ, a gene that is 
necessary for maintenance of the G2/M checkpoint through its ability to 
sequester the cyclinB/CDK1 complex in the cytoplasm (Chan et al., 1999).   
p53 also alters G2/M arrest through mechanisms involving topoisomerase 
II.  Topoisomerase II regulates chromatin structure by binding to DNA, creating 
double-stranded DNA breaks, and allowing torsional strain to be relieved by 
rotating one of the broken DNA strands prior to reannealing (Kingma and 
Osheroff, 1997).  Topoisomerase II is active during the G2/M transition while 
chromosomes are becoming highly condensed.  In response to cell stress, p53 is 
stabilized and can repress the promoter of topoisomerase II to initiate a G2/M 
arrest (Sandri et al., 1996).   
In addition to cell cycle regulatory genes, p53 also transcriptionally 
regulates genes involved in global genomic repair, as well as individual 
processes such as nucleotide excision repair (NER) and mismatch repair (MMR).  
The gene p53-induced ribonucleotide reductase 2 (p53R2) is a DNA repair 
protein that directly provides the substrates, deoxynucleotides, for DNA synthesis 
and repair (Tanaka et al., 2000).  Another well-known p53 target gene involved in 
DNA damage and repair, DNA damage binding protein 2 (DDB2), is responsible 
for the binding of DDB1 and the movement of repair complex to sites of lesions 
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(Hwang et al., 1999).  DDB2 is involved in the global genome repair pathway of 
NER (Stoyanova et al., 2009).  Nucleotide excision repair is a process that 
repairs pyrimidine dimers, a type of DNA damage resulting from UV radiation.  
During normal cell replication, base mismatches left uncorrected by the 
proofreading capabilities of DNA polymerases are addressed by mismatch repair 
(MMR).  p53 transcriptionally upregulates several key MMR genes including 
MLH1 (Chen and Sadowski, 2005), a gene that recruits enzymes to the site of 
repair; MSH2, which recognizes sites of damage (Scherer et al., 2000); and 
PCNA, a gene needed to facilitate repair of the mismatched base (Xu and Morris, 
1999).   
 
Role of p53 in Cellular Senescence 
 Cellular senescence is a process by which cells lose their ability to divide.  
Cells undergoing senescence exhibit a round and flattened morphology and can 
be identified by their expression of senescence-associated β-galactosidase (β-
gal).  β-galactosidase is a lysosomal hydrolase typically active at the low pH of 
4.0 but becomes active in senescent cells only at a pH of 6.0 (Dimri et al., 1995).  
Cellular senescence is induced by two unique pathways, both of which are 
regulated by p53.  The first mechanism, known as the telomere or aging 
pathway, occurs when cells undergo senescence as a result of critically 
shortened telomeres (Karlseder et al., 2002).  Alternatively, a second mechanism 
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of cellular senescence can be caused through a stress induced pathway such as 
oncogenic activation or DNA damage (Di Micco et al., 2006).   
In the telomere or aging model of senescence, cells undergo a limited 
number of cell divisions, at which time chromosomal telomeres reach a critically 
shortened length.  At this point, cellular senescence is induced to prevent 
permanent chromosomal damage, and detection of markers occur that are 
typically associated with DNA double-strand breaks, such as phosphorylated 
H2AX and foci consisting of DNA repair proteins (Takai et al., 2003).  
Additionally, senescent cells have activated Chk1 and Chk2 (d'Adda di Fagagna 
et al., 2003).  The Chk1 protein is necessary for telomere induced senescence as 
depletion of this kinase rescues cell cycle progression (d'Adda di Fagagna et al., 
2003).  During senescence, p53 is stabilized and can be detected at response 
elements of growth arrest genes, such as p21 and GADD45 (Jackson and 
Pereira-Smith, 2006).   
In the oncogenic model of senescence, cells permanently exit the cell 
cycle as a mechanism for protection against cellular transformation.  Ectopic 
expression of oncogenes such as K-ras and c-Myc will activate p14ARF to 
sequester the p53 negative regulator MDM2 and allow activation of p53 (Shay et 
al., 1991).  Recently, DEC1 was identified as a p53 target gene required for K-ras 
induced senescence (Qian et al., 2008).  DNA damage induction of senescence, 
on the other hand, requires ATM/ATR activation and phosphorylation of p53 that 
activates senescence (Alcorta et al., 1996).   
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Role of p53 in Regulation of Angiogenesis 
 Evidence suggests a tumor suppressive role for p53 through the inhibition 
of angiogenesis, or inhibiting creation of new blood vessels from pre-existing 
ones.  p53 can inhibit production of proangiogenic factors, increase the levels of 
endogenous angiogenic inhibitors, and interfere with other upstream activators of 
angiogenesis.  During tumor formation, angiogenesis is induced when tumor cells 
are exposed to hypoxic conditions.  Hypoxia inducible factor (Reef et al.) 
recognizes hypoxic signals and transcriptionally upregulates vascular endothelial 
growth factors for tumor angiogenesis (Liu et al., 1995).  p53 directly binds HIF 
and targets it for degradation (Ravi et al., 2000).  p53 also specifically activates a 
number of secreted antiangiogenic factors including thrombospondin-1 that 
negatively regulates angiogenesis by inhibiting proliferation and migration of 
endothelial cells (Dameron et al., 1994).  Increased expression of antiangiogenic 
collagens present in the basement membrane of blood vessels is another way 
that p53 inhibits angiogenesis (Teodoro et al., 2006).  Furthermore, p53-
mediated transcriptional repression of pro-angiogenic factors includes vascular 
endothelial growth factor (Pal et al., 2001), basic growth factor (Ueba et al., 
1994), and basic growth factor binding protein (Sherif et al., 2001; Subbaramaiah 
et al., 1999). 
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Role of p53 in Cell Movement and Migration 
 As tumors progress, cells metastasize from the primary site to nearby or 
distant locations.  During metastasis, tumor cells undergo cytoskeletal and 
morphological changes, as well as negotiate extracellular matrix barriers.  Cells 
first become polarized before sending out filopodia extensions that recognize 
barriers and interact with the environment (Timpson et al., 2001).   Rho GTPases 
(Rac1, Cdc42, and RhoA) and Rho kinases (ROCK) are a few of the proteins 
implicated at different stages in tumor progression to control cell protrusions and 
sense spatial information (Sahai and Marshall, 2003).  
p53 prevents cellular movement and migration by inhibiting filopodia 
formation and cell spreading downstream of the activity of Cdc42 (Gadea et al., 
2002; Gadea et al., 2004).  Cdc42 is activated at the extending front of a cell to 
form a complex that establishes cell polarity through a pathway that involves 
inactivation of glycogen synthase kinase 3b (GSK3b) (Etienne-Manneville and 
Hall, 2003).  p53 activates GSK3b through nuclear binding and stabilization, 
effectively stopping cell polarization (Watcharasit et al., 2002).  The p53-
dependent target gene LIM-kinase 2b (LIMK2b) is a known regulator of actin 
dynamics and further links p53 with cellular motility (Hsu et al.).   
 
p53 and apoptosis 
Apoptosis, or programmed cell death, is a normal physiological function 
essential for proper differentiation, development, and tumor suppression.  
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Apoptosis is characterized by morphology changes including plasma membrane 
blebbing, cell detachment, cell shrinkage, nuclear fragmentation, chromatin 
condensation, and chromosomal DNA fragmentation (Kerr et al., 1972).  
Apoptosis differs from necrosis in that it does not typically elicit an immune 
response as in the case with necrotic cell death. 
Induction of apoptosis occurs through two mechanisms.  The first known 
as the intrinsic pathway, results when cellular stresses signal through the 
mitochondria to activate the caspase cascade (Lee and Bernstein, 1995).  The 
second pathway, known as the extrinsic, or signal transduction pathway, is 
triggered by an interaction of extracellular ligands with transmembrane receptors 
that initiate activation of the caspase cascade and results in cell death 
(Bredesen, 2000).  p53 regulates both pathways of apoptosis through 
transcriptionally-dependent mechanisms.   
The p53-upregulated modulator of apoptosis (PUMA) was discovered as a 
direct target gene encoding two BH3 domains that allows binding to the Bcl-2 
proteins and release of cytochrome C from the mitochondria (Nakano and 
Vousden, 2001).  PUMA-deficient mice are unable to undergo p53-dependent 
apoptosis in response to ionizing radiation and cytokine withdrawal (Jeffers et al., 
2003).  Another p53-regulated apoptotic target gene, Noxa, contains a BH3 
domain that binds to Bcl-2, which is required for mitochondrial membrane 
permeabilization (Oda et al., 2000a).  A p53 target that plays a role in the intrinsic 
apoptotic pathway is the apoptotic protease activating factor 1 (APAF-1).  
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Following release of cytochrome C, APAF-1 oligomerizes to form the 
apoptosome and activates the caspase cascade through cleavage of 
procaspase-9 (Robles et al., 2001).   Evidence of p53-dependent apoptosis 
through activation of the extrinsic pathway occurs through transcriptional 
activation of Fas/CD95 and tumor necrosis factor family members (Fukazawa et 
al., 1999).  Tumor necrosis factors recruit adaptor molecules to bind and activate 
procaspase-8 cleavage, thus activating the caspase cascade (Burns et al., 2001; 
Li et al., 2003b).  The above described transcriptional targets are only a few of 
the many identified players in p53-dependent apoptosis. 
The biochemical signaling linking p53 to final cell fate is still not completely 
understood.  Many factors are associated with cell fate including the cell of origin, 
type and extent of cell stress, p53-specific post-translational modifications, and 
the presence of p53 interacting cofactors.  As mentioned previously, 
phosphorylation of p53 at serine-46 is associated with apoptosis.  Specifically, 
some reports suggests this post-translational modification is required for 
upregulation of unique p53 target genes, including the p53-regulated Apoptosis-
Inducing Protein 1 that functions to increase the mitochondrial membrane 
permeability and subsequent release of cytochrome C (Oda et al., 2000b).  The 
human cellular apoptosis susceptibility protein (hCAS) binds p53 apoptotic genes 
including p53AIP1 and PIG3, and hCAS suppression was sufficient to abrogate 
p53-dependent apoptosis (Tanaka et al., 2007). 
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In addition to the well-known transcriptional role of p53 in apoptosis 
described above, p53 also regulates apoptosis in a transcription-independent 
manner.  For example, DNA damage or hypoxic conditions can result in p53 
translocation from the nucleus to the mitochondria where the tumor suppressor 
can increase mitochondrial membrane permeabilization by directly interacting 
with proapoptotic proteins Bax and Bak at the outer mitochondrial membrane 
(Chipuk et al., 2004; Leu et al., 2004).  Additional support was provided by data 
showing that a transcription-independent role of p53 in apoptosis was observed 
when p53 mutants lacking the transcriptional activation domain still retained the 
ability to localize at mitochondria and induce apoptosis (Chipuk et al., 2004).  The 
transcription-independent role of p53 in apoptosis is controversial because it is 
difficult to fully separate the transcription-dependent and –independent 
mechanisms.  Data showing that PUMA and Noxa-deficient mice are unable to 
undergo p53-mediated apoptosis would argue against a transcription-
independent role of p53 during apoptosis.  Proponents of the transcription-
independent function of p53 suggest that only a basal level of the target genes 
Puma and Noxa is necessary in conjunction with the cytoplasmic functions of p53 
to induce apoptosis. 
 
Role of p53 in Autophagy 
 The term autophagy comes from the Greek roots ʻautoʼ, meaning self, and 
ʻphagyʼ, meaning to eat, thus making the appropriate reference to “eat oneself”.  
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Autophagy is most commonly studied as a response to cellular starvation; 
however, recent evidence shows that autophagy is also induced after cellular 
stresses, such as genotoxic damage.  There are several types of autophagy such 
as macroautophagy, microautophagy, and selective autophagy.  
Macroautophagy is a vacuolar process of self-digesting portions of the cellular 
cytoplasm, including long-lived proteins and/or damaged organelles.  This 
process begins with the formation of a double-membrane autophagosome that 
engulfs portions of the cytoplasm and later fuses with a lysosome containing 
degradative enzymes that breakdown larger macromolecules into monomeric 
components. These breakdown products are released into the cytoplasm and 
recycled by multiple cellular processes (Figure 2) (Berg et al., 1998; De Duve and 
Wattiaux, 1966).  Microautophagy refers to the direct uptake of cytoplasmic 
constituents for recycling through invagination of the lysosomal membrane.  The 
third type of autophagy is selective-autophagy that encompasses several 
processes including chaperone-mediate autophagy and pexophagy (Beau et al., 
2008).  Chaperone-mediated autophagy is a process whereby soluble 
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cytoplasmic proteins that contain a special targeting motif are transported to the 
lysosome using a chaperone complex.  The chaperone complex consists of 
hsc70 and co-chaperones that relocate proteins to the lysosomal membrane 
where the Lamp-2A receptor recognizes and translocates the cargo into the 
lumen of the lysosome for degradation (Kaushik et al., 2006).  Other forms of 
selective autophagy have been recently discovered in S. cerevisiae, including 
organelle specific autophagy known as pexophagy where receptors such as 
Pex3 and Pex14 on peroxisomes are recognized by the Atg associated proteins 
involved in autophagosomal formation (Farre et al., 2008).    
Nutrient sensing is the signal for many of the pathways that control 
autophagy including the mammalian target of rapamycin (mTOR) pathway; Ras 
and c-AMP-dependent protein kinase A that monitor glucose levels; insulin 
receptors and Akt signaling; and the ATP-sensing AMPK pathway.  In addition, 
various extra- and intracellular stresses can also activate the autophagy 
machinery including endoplasmic stress such as hypoxia (Yorimitsu et al., 2006), 
the accumulation of unfolded proteins (Bernales et al., 2006), pathogen infections 
(Gutierrez et al., 2004), and genotoxic stress such as chemotherapeutics 
(Munoz-Gamez et al., 2009).  All of these signaling pathways converge to 
activate the AuTophaGy-related (ATG) genes that constitute the core machinery 
for the process of autophagy (Tsukada and Ohsumi, 1993).  There are 
approximately 30 ATG genes involved in the different stages of autophagy that 
represent three major functional groups including i) the Atg9 and cycling 
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components, ii) vacuolar sorting proteins, and iii) the ubiquitin-like protein system 
(Xie and Klionsky, 2007). 
The role of autophagy in cancer is paradoxical in that the process is 
known to provide energy and pro-survival mechanisms that can be oncogenic 
signals; however, downregulation of autophagy gene expression in human 
cancer, and knockdown of autophagy genes in mouse models, support a role for 
autophagy in tumor suppression.  The first human gene discovered connecting 
autophagy and cancer was Beclin 1, that is monoallelically deleted in 50% of 
breast, ovarian, and prostate cancers (Shen et al., 2008; Yue et al., 2003).  A 
mouse model with monoallelic loss of Beclin 1 is viable but shows a higher 
incidence of lymphomas, lung and liver carcinomas, hyperplastic mammary 
glands, and acceleration of premalignant lesions induced by hepatitis B virus (Qu 
et al., 2003; Yue et al., 2003).  When Beclin 1 was ectopically expressed in the 
autophagy deficient MCF7 breast carcinoma cell line, that has minimal levels of 
Beclin 1 expression, functional autophagy was rescued and clonogenic survival 
decreased (Liang et al., 1999).  The UV irradiation resistance-associated gene 
(UVRAG) is a tumor suppressor mutated at high frequency in colon cancer and 
identified as a positive regulator of Beclin 1 as well as a promoter of autophagy 
(Liang et al., 2007). 
In addition to the direct role of these autophagic players in cancer, a 
number of upstream autophagy regulators are tumor suppressors and 
oncogenes.  The class I phosphoinositide 3-kinase (PI3K-I) is a known oncogene 
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activated via receptor tyrosine kinases leading to cell growth and inhibition of 
autophagy by activating mTOR (mammalian target of rapamycin).  PI3K is 
frequently activated in sporadic cancer where receptor tyrosine kinases are 
mutated, subsequently turning on mTOR and inhibiting autophagy (Petiot et al., 
2000).  The tumor suppressor, STK11 (serine/threonine kinase 11) is mutated in 
patients with hereditary intestinal polyposis that increases the risk of cancer by 
90% at age 70 (Rustgi, 2007).  STK11 positively induces autophagy through 
activation of AMPK signaling (Liang et al., 2007).  Another well known tumor 
suppressor ARF (alternative reading frame of CDKN2A) sequesters MDM2, 
allowing accumulation of p53 levels and activation of p53 following oncogenic 
stress signals.  ARF can induce autophagy in p53-dependent and –independent 
manners.  The short mitochondrial ARF isoform induces autophagy and 
subsequent caspase-independent cell death that can be rescued with knockdown 
of ATG5 or Beclin 1 (Reef et al., 2006).  Additionally, ARF directly interacts with 
Bcl-xL that normally protects cells from autophagy by inhibiting Beclin 1 activity 
(Pimkina et al., 2009). 
p53 acts as a positive and negative regulator of autophagy.  Furthermore, 
p53 can regulate autophagy in transcription-dependent and –independent 
manners.  p53 acts in a transcription-independent function to negatively regulate 
autophagy.  Expression of p53 in the p53-null HCT116 cell line rescued baseline 
autophagy to the same levels as p53-proficient HCT116 cells (Tasdemir et al., 
2008).  Moreover, the role of p53 as an inhibitor of autophagy was confirmed 
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when ectopic expression of wild-type p53, a p53-DNA binding mutant, and a p53-
cytoplasmic only variant all consistently showed repressive effects on autophagy  
(Morselli et al., 2008; Tasdemir et al., 2008).  
The more widely described role of p53 in autophagy is through the 
transcription-dependent induction of autophagic activity following cellular stress.  
Autophagy is induced following numerous cellular stress signals that also activate 
p53 such as starvation, hypoxia (Levine and Abrams, 2008), endoplasmic 
reticulum stress, oxidative stress (Feng et al., 2005), and DNA-damage 
(Katayama et al., 2007).  p53 upregulates the β1 and β2 subunits of AMP-
activated protein kinase that act as a sensor of intracellular energy stores and 
stimulates autophagy by phosphorylating the TSC1/TSC2 complex that directly 
inhibits mTOR (Feng et al., 2007).  In addition, p53 regulates the upstream 
activators of AMPK, Sestrin1 and Sestrin2, after genotoxic and oxidative stress 
conditions, to induce autophagy (Budanov and Karin, 2008).  p53 can also bind 
and directly regulate TSC2 after genotoxic stress further linking p53 to the mTOR 
pathway through induction of this mTOR inhibitor (Feng et al., 2007).     
DAPK-1 and DRAM1 are two additional novel connections between p53 
and autophagy.  DAPK-1 is regulated in a p53-dependent manner in numerous 
cell lines in response to adriamycin and ionizing radiation and is epigenetically 
silenced during tumorigenesis (Gozuacik and Kimchi, 2006; Martoriati et al., 
2005).  Since its discovery as a p53 transcriptional target, publications have 
described the role of DAPK-1 in autophagy induction, including its ability to 
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phosphorylate Beclin 1, resulting in its disassociation from Bcl-xL (Harrison et al., 
2008; Zalckvar et al., 2009).  The damage-regulated autophagy modulator 
(DRAM) is regulated by p53 and its family member p73 but is only necessary for 
p53-mediated autophagy induction (Crighton et al., 2007).  DRAM is lysosomal in 
location, induces markers of autophagy, and decreases cell survival but the exact 
mechanism by which it functions in autophagy has not been deciphered (Crighton 
et al., 2006).  Through work completed in our laboratory, p73 binds and regulates 
a number of transcriptional targets involved in autophagy and metabolism 
including ATG5 and ATG7 (Rosenbluth et al., 2009).  In Chapter IV of this 
dissertation, I described the ISG20L1 gene and its functional characterization as 
a direct target of p53 and the family members, p63 and p73.  Further, ISG20L1 
induces autophagy in response to multiple genotoxic stresses, providing further 
evidence that p53 acts to promote DNA damage-induced autophagy. 
 
Overall Goals of Dissertation Research 
 One focus of research in the Pietenpol laboratory is deciphering unique 
and overlapping functions of the p53 family of transcription factors.  Multiple 
findings from our laboratory have contributed to the current understanding of how 
p53 and p63 coordinate cell fate decisions in response to stress and 
differentiation cues (Perez et al., 2007). Further, we recently defined the p73 
cistrome and used this dataset to gain mechanistic insight to the role of p73 in 
differentiation and tumorigenesis (Rosenbluth et al., under review).   p53, p63, 
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and p73 have approximately 1600, 5800, and 7600 binding sites in the genome, 
respectively (Rosenbluth et al., 2008; Smeenk et al., 2008; Yang et al., 2006).  
To date approximately 150 genes are documented as direct p53 target genes. 
The goal of this dissertation is to identify novel p53 family transcriptional target 
genes and mechanistically characterize their functions in biologically-relevant 
processes downstream of the p53 family signaling axis. 
In Chapter III of this dissertation, I describe the use of statistical and 
bioinformatic tools to perform genomic analyses and identify a subset of novel 
p53 transcriptional targets.  Further, I describe current and future plans to 
analyze these target genes, in a high-throughput manner, and identify the 
contribution of each to p53-regulated processes such as cell cycle arrest, 
apoptosis, and autophagy, among others. 
 In Chapter IV of this dissertation, I describe the identification of ISG20L1 
as a target gene of the p53, as well as its family members p63 and p73.  Further, 
I show that ISG20L1 acts downstream of p53 as a modulator of autophagy. 
 Lastly, in Chapter V of this work I will summarize the findings and 
significance of my completed research.  I will further describe the questions that 
arise from this work and remain unanswered in the fields of p53 and autophagy.  
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
 
Cell Culture 
 
The RKO, U2OS, H460, 293FT, HCT116, and H1299 cell lines were 
obtained from  ATCC and cultured in DMEM medium with 10% fetal bovine 
serum supplement and 1% penicillin-streptomycin.  The MDA-MB-231 were 
obtained from ATCC and cultured in McCoyʼs 5A-Dulbeccoʼs modified Eagleʼs 
medium (Invitrogen).  The ATG5+/+ and ATG5-/- MEFs were a kind gift from  Dr. 
Mizushima (Tokyo Medical and Dental University)  and cultured in DMEM 
medium with 10% fetal bovine serum (Kuma et al., 2004).  The MDA-MB-231 
was also obtained from ATCC and cultured in McCoyʼs 5A medium.  The Rh30 
cell line was kindly given by Peter Houghton (St. Jude Childrenʼs Research 
Hospital) and cultured in RPMI medium with 10% fetal bovine serum.  
The ecdysone-inducible expression system (Invitrogen, Carlsbad, Ca) was 
used to generate cell lines that conditionally express p53.  A human 
hemaglutinin-tagged p53 cDNA was ligated into the pIND vector.  The resulting 
vector pIND-p53 was cotransfected with the pVgRXR vector into the human large 
cell lung carcinoma H1299, which is null for p53 family member expression.  
Stable clones were selected by limiting dilution of G418 (Mediatech) and Zeocin 
(Cayla) and the resulting cell lines were named H1299-inducible p53 (Hip53).  
The Hip53 ponasterone A-inducible p53 cell lines were cultured in DMEM 
  36 
supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 600 
µg/mL G418 (Mediatech, Herndon, VA), and 400 µg/mL zeocin (Cayla, Toulouse, 
France).  All cells were grown at 37°C with 5% CO2. 
Primary human foreskin epidermal keratinocytes (NHEKs) were obtained 
from the Vanderbilt Skin Disease Research Core.  NHEKs were isolated by 
collecting human foreskins in a 1:1 mixture of Dulbeccoʼs modified eagle medium 
(DMEM) and nutrient mixture F-12 HAM (DMEM-F12) (Gibco, Gaithersburg, MD) 
supplemented with 5% fetal bovine serum (FBS) (dialyzed to remove calcium 
ions), and 50 µg/mL gentamicin (Gibco) and stored at 4°C.  Foreskins were 
washed 3 times for 15 min each time in DMEM-F12 supplemented with 
gentamycin and 1% penicillin-streptomycin.  Excess dermis was trimmed away 
and the dermal side of each foreskin was lightly scored with a sterile scalpel.  
The foreskins were placed dermis-side down on sterile filter paper and incubated 
in DMEM-F12 containing 0.25% bovine pancreas trypsin (Sigma Chemical 
Company, St. Louis, MO), 0.04% disodium ethylenediamine tetracetic acid 
dehydrate (EDTA), 50 µg/mL gentamycin, and 1% penicillin-streptomycin 
overnight at 4°C.  After trypsinization, the epidermis was separated from the 
dermis, rinsed in DMEM-F12, minced, and then incubated in EpiLife keratinocyte 
growth medium (Cascade Biologics, Portland, OR) supplemented with human 
keratinocyte growth supplement (HKGS) (Cascade Biologics) and 50 µg/mL 
gentamicin fro 20 minutes at 37°C.  The epidermis was triturated with a pipet, 
and any remaining trypsin was inactivated with excess media containing 5% 
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dialyzed FBS (Sigma).  Cells were centrifuged at 500 rpm for 10 min, 
resuspended in keratinocyte growth medium, and palted.  For all experiments, 
NHEKs were cultured in EpiLife keratinocyte growth medium (Cascade 
Biologics). 
Primary human mammary epithelial cells (HMECs) were purified from 
normal breast tissue obtained by the Vanderbilt- Ingram Cancer Center Human 
Tissue Acquisition and Pathology Shared Resource Core and grown in DMEM 
serum supplemented with 10% fetal bovine serum, 0.2% gentamicin, 1% 
fungizone, and 1% penicillin-streptomycin, and stored for no more than 48 h prior 
to epithelial cell preparation.  The exterior of the tissue was trimmed off with a 
sterile scalpel and weighed.  Tissue is washed three times with sterile PBS and 
0.2% gentamicin, 1% fungizone, and 1% penicillin-streptomycin and then minced 
with sterile scissors and placed in a sterile 500 mL flask.  For every 10 g of 
tissue, 35 mL of Digestion Media were added.  The Digestion Media is composed 
of Human Mammary Fibroblast Medium supplemented with 1 mg/Ml of 
collagenase (Sigma) and 0.2 mg/mL hyaluronidase (Sigma).  The tissue was 
incubated with shaking at 37°C for 12 h.  The cell mixture was transferred to 
sterile 50 mL conical tubes, spun at 1000 rpm for 10 min, resuspended in Human 
Mammary Fibroblast Medium, and plated.  The plated cell mixture was placed at 
37°C with 5% CO2 in a humidified incubator for 2 h, allowing the fibroblasts to 
attach to the tissue culture dish.  The media containing non-adherent cells was 
collected and spun at 1000 rpm for 10 min.  The cell pellet was resuspended and 
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cultured in growth media.  The HMEC growth media is composed of DMEM/F12 
medium 1:1 supplemented with 1.0 µg/mL insulin (Humulin R, Eli Lilly and Co.), 
1.0 µg/mL hydrocortisone (Sigma), 10  µg/mL ascorbic acid (Sigma), 12.5 ng/mL 
human recombinant EGF (Gibco), 10 µg/mL apotransferrin (Sigma), 0.1 mM 
phosphoethanolamine (Sigma), 2.0 nM beta-estradiol (Sigma), 10 nM 3,3ʼ5-
triiodo-L-thyronine sodium salt (Sigma), 15 nM sodium selenite (Sigma), 2.0 mM 
L-glutamine, 1% penicillin-streptomycin, 1 ng/mL cholera enterotoxin (ICN 
Biomedicals, Inc.), 1% fetal bovine serum, and 35 µg/mL bovine pituitary extract 
(Gibco).  Experiments and protocols involving HMECs were approved and 
considered to meet the criteria for Exempt Review by an Institutional Review 
Board Health Sciences Committee at Vanderbilt University. 
 
Cell Treatment 
 The following chemotherapeutics were used in treatment of cell lines 
mentioned above as described in results 8 Gy 137Cs ionizing radiation, 0.13 mM 
5-FU (APP Pharmaceuticals), 20 µM etoposide (Bedford Laboratories), 5 µg/mL 
cisplatin (APP Pharmaceuticals), 5 nM paclitaxel (Sigma), 40 nM rapamycin 
(Calbiochem).  Lysosomal inhibitors were used at final concentration of 10 µg/ 
mL of E64d (Calbiochem 330005) and pepstatin A (MP Biomedical 195368).   
The Hip53 cells were treated with 10 µM ponasterone A. 
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Cell Transfection and Small Interfering RNA 
The following targeting sense strand sequences were used for siRNA: 
Dharmacon siControl (Non-Targeting siRNA #1) UAGCGACUAAACACUCAA; 
Dharmacon siISG20L1-1 CAGCAAGGUUCACGGAUAUUU; siISG20L1-2, 
AUACUAAGCAAGCGAGGGAUU; siISG20L-3, 
CUCAAUUGGAAACGUGAAAUU.  Dharmacon siRNA ISG20L1 pools consisted 
of the above targeting vectors plus siISG20L1-4 CAGCAGGGCCACUCGUCUA.  
Dharmacon siRNAs were reverse transfected into H460, U2OS, and RKO cells 
(4.5 x 105) with Lipofectamine2000 (Invitrogen) according to the manufacturerʼs 
protocol.   
To knockdown p53 in NHEK cells, a 19-bp short hairpin RNA, 
corresponding to nucleotides 611 to 629 of p53 RNA (GenBank NM000546), was 
annealed and cloned into the self-inactivating lentiviral vector (H1-LV) that 
contains a GFP reporter gene under control of human ubiquitin C promoter for 
monitoring infection efficiency.  A scrambled oligonucleotide was designed as a 
negative control and also cloned in the H1-LV vector.  These lentiviral vectors 
were transfected using CaPO4 methods into 293FT cells.  After 48 h viral medium 
was harvested and with the addition of 8 µg/mL polybrene used to infect NHEK 
cells. 
293FT cells were transfected using Fugene 6 (Roche) to make pSico 
lentivirus.  To knockdown p73 in MDA-MB-231 and Rh30, cells were infected with 
the pSico lentivirus system that expresses shRNA targeting all isoforms of p73. 
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 Forty-eight h later, cells were treated with rapamycin (40 nM) and RNA 
harvested 24 h later.  The shRNA targeting p73 sequence used in the pSico 
lentivirus is 5ʼ-TCAAGGAGGAGTTCACGGA-3ʼ. 
293FT cells were transfected using Lipofectamine2000 with either pCEP4 
empty control or cDNAs encoding p53, TAp63γ, TAp73β, or ΔNp63α and 
harvested 24 h later for RT-PCR or Western analysis. 
Clonogenic Survival Assays were performed in HCT116, RKO, H1299 
cells, as well as ATG5+/+ and ATG5-/- MEFs transformed with SV40 large T 
antigen obtained from Dr. Mizushima (Kuma et al., 2004).  For all cell lines, 
Lipofectamine2000 was used to transfect either pCEP4 empty vector control or 
ISG20L1 in 60 mm dishes.  Twenty-four h after transfection, cells were selected 
for 10 days under the appropriate hygromycin B concentration determined per 
cell line.  Colonies were Wright stained and analyzed using the Biorad Quantity 
One software. 
 
Protein Lysate Preparation 
 Cells were washed with ice-cold PBS and harvested in lysis buffer (50 mM 
Tris-HCL [pH 7.4], 100 mM NaCl, 0.5% Nonidet P-40, 4 mM EDTA, 1 mM 
dithiothreitol) supplemented with 50 mM NaF, 0.2 mM Na Vanadate, and the 
protease inhibitors antipain (10 µg/mL) (Sigma), and 4-(2-aminoethyl)-
benzenesulfonylfluoride (200 µg/mL) (Calbiochem, San Diego, CA).  Cells were 
incubated on ice for 1 h, and the protein supernatant was clarified by 
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centrifugation at 13,000 g for 15 min at 4°C.  Protein concentration was 
determined by the Bio-Rad Protein Quantification Kit (Bio-Rad Laboratories, 
Hercules, CA). 
 
Western Analysis and Antibodies 
Protein lysates were boiled in 1x Laemmli sample buffer, separated by 
SDS-Page, and transferred them to Immobilon-P membranes (Millipore, Billerica, 
MA) for Western analysis.    Membranes were blocked with 5% non-fat dry milk in 
TTBS (100 mM Tris-HCL [pH 7.5], 150 mM NaCl, 0.1% Tween-20) and then 
incubated in the antibodies mentioned below prepared in 1% non-fat dry milk.  
Fourteen percent SDS-polyacrylamide gels were used for analysis of LC3 using 
anti-MAP1LC3-II (Abgent AP1802a).  Additional antibodies used for protein 
detection: anti-p53 (Santa Cruz Biotechnology, PAb1801), anti- β−Actin (Sigma-
Aldrich, A5441- 0.2 mL), anti-PARP (Cell Signaling, #9542), anti- Caspase-3 
(Cell Signaling, #9662), anti-p73 (Bethyl A300), p63 (4A4) (Santa Cruz, sc-8431), 
and anti-ISG20L1 (Bethyl Laboratories, rabbit affinity purified antibody).  A 
peptide for ISG20L1 antibody production was designed at the C-terminus of 
ISG20L1, outside of the functional exonuclease domain found from amino acids 
111-275, with the intent to increase antigenicity and accessibility of the antibody 
while decreasing possible cross-reactivity.  The peptide product sequence 
“HGSRGGAREAQDRRN” targets amino acids 311-325 of ISG20L1 and these 15 
amino acids are unique to the ISG20L1 sequence.   
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RNA Isolation and Real-Time Analysis 
Total RNA was purified, reverse transcribed and quantitative real-time 
PCR was performed by the following:  RNA isolation was done using the Aurum 
Total RNA Mini kit (Bio-Rad), and reverse transcription of 500 ng of mRNA was 
performed using the TaqMan Reverse Trasncription Reagents kit (Applied 
Biosystems, Carlsbad, Ca) to generate cDNA.  The cDNA samples were diluted 
1:4 and 2 µl were used for qRT-PCR.  Reactions were performed using the iQ 
SYPBR-Green Supermix (Bio-Rad).  All primer sequences were obtained using 
the Primer3 resource at (http://frodo.wi.mit.edu/primer3/) (Rozen and Skaletsky, 
2000).  All primer sets were run under the following cycling conditions: 95°C for 3 
minutes followed by 40 cycles of: 95°C for 10 sec and annealing at 60°C for 45 
sec, with data acquisition during each cycle on an iCycler Thermal Cycler (Bio-
Rad).  Melting curve analysis following PCR cycling was used to determine purity 
and quality of PCR product. 
 
 RNA isolation and microarray experiments 
 The Hip53 cell model was used with treatment of ponasterone A to induce 
p53 activity for 24 h and the control vector alone cell line was also used.  
Experiment was performed in duplicate.  RNA was isolated using the Aurum 
Total RNA Mini Kit (Bio-Rad) without addition of β-mercaptoethanol and 
submitted to the VMSR for quality control.  The RNA was processed and 
microarray was hybridized by the VMSR.  Microarray data analyses was 
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performed using the ArrayAssist software platform (Stratagene).  A list of probes 
was created with fold-change in gene expression for p53 induced samples versus 
pVgRXR control. 
 
Immunofluorescence, Immunohistochemistry, and Electron Microscopy 
For immunofluorescence analysis, cells were grown on glass coverslips 
and fixed in a 4% paraformaldehyde solution for 10 min at room temperature.  
After rinsing with PBS, the cells were permeabilized with 0.5% Triton X-100 for 
10 mins.  Following another rinse with PBS, cells were blocked for 15 min at 
room temperature with 5% BSA-PBS solution.  The ISG20L1 (Bethyl) and FLAG 
antibodies (Sigma, F3165 anti-FLAG M2) were diluted in 1% BSA-PBS and 
incubated on cells at 37°C with 5% CO2 for 1 h.  The coverslips were washed 3x 
with PBS and placed in 2° rabbit anti- Alexa Flour 546 and mouse anti- Alexa 
Flour 488, respectively for 1 h at room temperature, in the dark.  The cells were 
washed 3x with PBS and counterstained with DAPI.  All images were obtained 
using 1000x magnification on a Zeiss Axioplan microscope equipped with a Zeiss 
camera and software. 
Direct immunofluorescence was performed on U2OS cells stably 
expressing mRFP-GFP-LC3.  The mRFP-GFP-LC3 expression vector was kindly 
provided by Dr. Yoshimori (Osaka University) (Kimura et al., 2007) and Dr. 
Mizushima (Tokyo Medical and Dental University).  U2OS stably expressing the 
tagged LC3 protein were generated by transfecting the cells with the mRFP-GFP-
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LC3 expression vector using FuGENE 6 (Roche, Indianapolis, IN) and selecting 
in geneticin (Cellgro, Manassas, VA).  Engineered U2OS cells were then 
transfected with either pCEP4 control or ISG20L1 expression plasmids and 
treated for 24 h with 5-FU.  The cells were fixed and analyzed as above using a 
Zeiss Axioplan.  Fifty cells were counted, without knowledge of the plasmids 
expressed, and RFP-only foci are reported as a percentage of total foci.  
For immunohistochemistry analysis, cells were grown on glass coverslips. 
 The cells were fixed, and permeabilized as indicated above for IF analysis.  
Washes were done in 1x TBS/0.1% Tween- 20 (1x TBST), and cells were 
blocked overnight rocking at 4°C in 5% normal goat serum diluted in TBST.  The 
coverslips were stained specifically for the cleaved LC3 using the Abgent LC3 
specific 1° antibody (Abgent AP1806a) for 30 mins at room temperature.  The 
coverslips were then washed 3 times in TBST.  The secondary used was the 
Dako Cytomation LSAb2 system HRP kit (K0673) according to manufacturerʼs 
protocol.  Cells were analyzed for LC3 staining and counted at 200x 
magnification. 
 U2OS cells were reverse transfected using Lipofectamine2000 with 
Dharmacon Nonsilencing control or siRNA targeting ISG20L1.  Three days after 
reverse transfection, cells were treated or not for 24 h with 5-FU to induce 
autophagy.  Cells were harvested, washed with PBS, and exposed to 2% 
glutaraldehyde for fixation.  Sample were rinsed in buffer, postfixed in 1% OsO4 
for 1 h, dehydrated through an ethanol series and transferred into Epon resin.  
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Ultrathin sections (60–70 nm, silver-gray) were obtained using a Reichert Ultracut 
E microtome with a diamond knife, transferred to formvar-coated grids, and 
examined on a Phillips CM-10 transmission electron microscope (FEI, Hillsboro, 
OR), operating at 80 kV, and images were captured with an AMT 2 mega pixel 
camera (Advanced Microscopy Techniques, Danvers, MA).   
Two replicates were performed and each time 25 micrographs were 
counted blindly for each control and ISG20L1 knockdown.  Additionally, cells 
were photographed in an un-biased fashion according to their placement on the 
grid.  Images were quantified using ImageJ software and taking into account 
various acceptable methods (Klionsky et al., 2008; Swanlund et al.).  We set to 
scale the pixel ratio to microns and used measurement analysis to quantify the 
area occupied by autophagosome and autolysosomes as compared to the total 
cytoplasmic area excluding the nucleus.  Autophagosomes were defined as 
double or multiple membrane structures surrounding cytoplasmic material, and 
autolysosomes were defined as single membrane structures surrounding 
cytoplasmic constituents and various levels of degradation (Mizushima et al., 
2001).   
 
Flow Cytometric Analyses 
Flow cytometry was performed by incubating 1 x 106 cells in 20 µg/mL 
propridium iodide (Sigma-Aldrich) and measuring DNA content for 15,000 events 
using a FACSCaliber instrument (Becton- Dickinson) (Stewart and Pietenpol, 
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1999).  Flow cytometry data were plotted using CellQuest software (Becton, 
Dickinson & Co).  Annexin V-FITC staining detected by flow cytometry was 
performed using the Annexin V-FITC apoptosis detection kit (BD Pharmingen, 
556547). 
 
Chromatin Immunoprecipitation Analyses 
 HMECs were treated or not with 10 ug/mL cisplatin for 24 h and 
chromatin was prepared(Szak et al., 2001).  Growth media was aspirated from 
cells and replaced with 1.6% formaldehyde (EM Science, Gibbstown, NJ) 
solution in PBS.  Cells were incubated in formaldehyde for 10 min at room 
temperature, followed by inhibition of the crosslinking reaction by the addition of 
glycine for a final concentration of 0.125 M.  After 2 min incubation, cells were 
washed twice with PBS.  Extracts were prepared by scraping cells in 1 mL of 
lyses buffer as above.  Sonication of the cell lysates was performed to yield 
chromatin fragments of approximately 500-1000 bp, and debris was pelleted by 
centrifugation for 10 min at 13,000 x g, and 1- 1.5 mg of total protein extracts was 
pre-cleared with 10 µg of isotype matched antibody (Pierce, Rockford, IL) bound 
to PAS for 1 h with rocking at 4°C.  The extracts were immunoprecipitated with 1 
µg of the respective antibodies by rocking overnight at 4°C.  Immunocomplexes 
were washed twice with buffer, four times with wash buffer (100 mM Tris [pH 8.5], 
500 mM LiCl, 1% Noniodet P-40, 1% deoxycholic acid), followed by two more 
washes in lyses buffer.  The protein was degraded in digestion buffer (120 µg/mL 
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Proteinase K, 10 mM Tris [pH 7.5], 5 mM EDTA, and 0.5% SDS) at 56°C 
overnight, and then incubated at 65°C for 30 min.  The DNA was resuspended in 
40 µ water, and 2 µl of each sample were used for PCR amplification. 
 PCR amplification was performed using primers ISG20L1 forward 
CAGCCTGTCCAACATGGC and ISG20L1 reverse 
GCTGAGGCCATAACTTGGAAA, GAPDH forward  
CACCAGCCATCCTGTCCTCC and GAPDH reverse 
GTTCCTTCCCAGCCCCCACT, and p21 forward              
GCTTGGGCAGCAGGCTG and p21 reverse AGCCCTGTCGCAAGGATC as 
previously described (Schavolt and Pietenpol, 2007).  PCR was performed using 
one cycle of 5 min at 95°C; followed by different number of cycles as indicated 
below of: 95° for 30 s, annealing temperature as indicated below for 45 s, and 30 
sec of 72°C; to be finished with 10 min at 72°C.  AEN 40 Cycles Anneal 54°C, 
GAPDH 35 Cycles Anneal 62°C, and p21 35 Cycles Anneal 57°C.  Amplified 
DNA was resolved on a 6% polyacrylamide gel and stained after with ethidium 
bromide. 
To attain sufficient levels of p73 for ChIP analysis, ~1.7 x 107 rapidly 
growing Rh30 cells were treated for 24 h using vehicle control or 40 nM 
rapamycin.  The samples were prepared and Genpathway analysis performed  
using the p73 antibody (Bethyl Laboratories, A300) for immunoprecipitation. 
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DNA Laddering 
 Cells were counted and 2 x 106 cells were removed and washed in PBS 
for DNA laddering analysis.  Procedure was followed according to the Roche 
Apoptotic DNA-Ladder Kit (11 835 246 001).  In brief, cells were lysed in an equal 
volume of proprietary lysis buffer, incubated for 10 min at room temperature, 100 
µl of isopropanol was added and vortexed prior to loading the sample onto filter 
tubes.  Filter tubes were spun 2x 1 min at 8000 rpm and washed after each spin 
with 500 µl washing buffer.  After discarding flow through, filter tube samples 
were placed in collection tubes and 100 µl elution buffer was added and then 
spun for 1 min at 8000 rpm.  DNA obtained from samples was run on a 1% 
agarose gel next to 1 kb DNA ladder and positive control DNA (U937 cells 
treated with camptothecin) supplied from Roche. 
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CHAPTER III 
 
 
 
IDENTIFICATION OF NOVEL P53 FAMILY TRANSCRIPTIONAL TARGETS 
 
 
 
Introduction 
 
 The tumor suppressor p53 functions as a sequence-specific DNA binding 
protein that regulates the expression of genes involved in cell-cycle arrest, 
apoptosis, DNA repair, senescence, cell growth, and anti-angiogenesis 
(Pietenpol et al., 1994).  Stress signals including DNA damage, oncogenic 
activation, metabolic changes, and hypoxia activate p53  (Debbas and White, 
1993; Graeber et al., 1994; Imamura et al., 2001; Kastan et al., 1991; Reisman et 
al., 1993; Zhan et al., 1993).  As a transcription factor, p53 binds a degenerate 
DNA sequence consisting of 2- 10 bp decamers with palindromic sequences 5ʼ-
PuPuPuC(A/T)(T/A)GPyPyPy-3ʼ separated by a 0- 13 bp spacer (pu= purine and 
py= pyrimidine) (el-Deiry et al., 1992).  In addition to variations within the 
consensus binding sequence, p53 binding at specific target genes is affected by 
p53 protein levels and post-translational modifications; co-factors; and 
accessibility of the binding site as determined by chromatin structure.  Many of 
the p53 transcriptional targets that are well characterized and often used as 
positive controls were discovered in a one-gene-at-a-time approach, including 
p21 and MDM2 (el-Deiry et al., 1993; Honda et al., 1997).  The first attempt to 
estimate p53 binding sites across the genome was based on data derived from a 
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yeast-based one-hybrid (Tokino et al., 1994).  Based on the fifty-seven p53 sites 
identified, results were extrapolated to suggest that there were between 200 to 
300 total p53 binding sites in the genome (Tokino et al., 1994).  Several years 
later, the advent of oligonucleotide arrays allowed identification of putatively all 
p53 binding sites on chromosomes 21 and 22.  From this data, the authors 
suggested that 1,600 binding sites existed in the entire genome (Cawley et al., 
2004).   For comparison, c-Myc was estimated to have 25,000 binding sites from 
the same study (Cawley et al., 2004).  To date, only 150 of the approximate 
1,600 putative transcriptional targets (assuming each binding site corresponds to 
regulation of one gene or one non-coding RNA ʻgeneʼ) have been functionally 
characterized downstream of p53 signaling. 
 The p53 family members, p63 and p73, share an approximately 60% 
sequence identity with p53 in the DNA binding domain (Yang et al., 2006).  Work 
performed in our laboratory and others have suggested that each family member 
has unique binding specificity.  For example, p63 selectively binds A/G at position 
5 and C/T at position 16 of the 20 bp response element (Perez et al., 
2007)(Rosenbluth et al, not yet published).   The family members have both 
unique and overlapping functions through their control of  transcriptional targets.  
p63 and p73 can bind and regulate a number of well-characterized p53 
transcriptional targets including p21, GADD45, PERP, and MDM2 (Barbieri and 
Pietenpol, 2005; Zhu et al., 1998).  Similar to p53, its family members are known 
to be modulated after exposure of cells to DNA-damage.  For example, cisplatin-
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elevates p73 activity (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) 
and UV radiation, paclitaxel, actinomycin D, bleomycin, and etoposide induce 
endogenous TAp63 activity (Gressner et al., 2005; Katoh et al., 2000; Okada et 
al., 2002).   
In addition to the large number of possible overlapping targets amongst 
the p53 family members, each has target genes it uniquely regulates as 
demonstrated best in the distinct phenotypes of the respective p53 family knock-
out mice.  Unlike the p53-null mouse model, that develops normally, for the most 
part, but has an increased incidence of tumorigenesis, the p63- and p73-null 
mouse models show defects in epithelial and neuronal development, respectively 
(Donehower et al., 1992; Yang et al., 1999; Yang et al., 2000)  These mouse 
models suggest that p63 and p73 play unique roles in development and 
differentiation.  p63 and p73 transcriptionally regulate target genes not regulated 
by p53, such as Wnt4 that is necessary for the development of several organs 
including ovarian follicles (Osada et al., 2005).  Recently, microarray gene 
expression analysis was performed on RNA harvested from p53-, p63-, or p73- 
null MEFs after DNA damage.  From this dataset each p53 family member 
uniquely regulated approximately 100 genes (Lin et al., 2009).  Data from these 
studies also suggest that p63 and p73 play a role in tumor suppression as they 
regulate a number of target genes involved in the DNA damage response and 
DNA repair.  
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 Utilizing genomic technology our laboratory and others have identified 
numerous candidate target genes, both unique and overlapping for p53, p63, and 
p73-dependent regulation.  We used a number of criteria to select p53 target 
genes to further characterize including: 1) identification of a p53 binding site 
within 20 kB of a select gene as determined by ChIP analyses, 2) differential 
regulation of a given gene by p53 as assayed by gene expression microarray, 
and 3) rank of a putative transcriptional target as determined by mathematical 
algorithms.  To date, I have identified approximately 150 genes as putative p53 
targets using the criteria listed above.  My dissertation research was focused on 
functionally characterizing a select number of these genes and linking these 
genes to biologically relevant pathways downstream of p53 signaling. 
 
Results 
In order to increase the probability of identifying genes directly regulated 
by p53 and functionally significant in tumor suppression, I applied a panel of 
selection criteria to a number of datasets generated in our laboratory and 
available in silico.  These selection criteria included: presence of a p53 binding 
site identified by ChIP analysis within 20 kB of a select gene and differential 
regulation of a gene by p53 as determined by gene expression microarray 
analyses.  By using datasets generated from several different cell lines and 
conditions, we sought to eliminate cell type- or DNA damage- specific bias.  After 
creation of a subset of putative target genes that are bound and regulated by 
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p53, we further analyzed the placement of these genes in the ranking predicted 
by the mathematical modeling algorithms applied to p53 gene expression 
analysis.  Lastly, we compared the putative p53 targets with previously identified 
p63 and p73 transcriptional targets to determine unique and coordinate 
regulation (Figure 3). 
 
ChIP-Based Datasets 
To compile a comprehensive set of genomic p53 binding sites, we used 
ChIP-based datasets from several sources.  The first was from our laboratory.  
Dr. Jamie Hearnes, a previous graduate student in the Pietenpol laboratory, 
identified p53-regulated target genes by combining ChIP with a yeast one-hybrid 
selection system (Hearnes et al., 2005).  Libraries were generated from primary 
human mammary epithelial cells (HMECs) and an immortal non-transformed 
breast cell line MCF-10A, both of which had been treated with adriamycin, a DNA 
intercalating agent that induced cell cycle arrest under these conditions (Hearnes 
et al., 2005).  From these cells p53-bound fragments were purified and cloned 
into a yeast expression system upstream of the HIS3 gene and transformed into 
an auxotrophic histidine-deficient yeast-strain with a galactose-inducible 
expression vector containing the p53 gene.  This allowed for selection of yeast 
transformants, the growth of which was dependent on p53-mediated transcription 
from select human genomic fragments.  The ChIP-yeast screen identified  
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genomic binding sites upstream of previously known p53 target genes including 
MDM2, p21, and DDB2.  An additional 100 novel genomic binding sites were 
identified upstream of putative p53 target genes such as RPS27L (ribosomal 
protein 27-like) that was recently validated as part of the p53-dependent 
apoptotic pathway (He and Sun, 2007) as well as FLJ12484/ ISG20L1 that will be 
further discussed in Chapter IV of this dissertation.   
In 2006, the first genome-wide ChIP analysis was performed using p53 
binding sites by combining ChIP with paired-end ditag sequencing (ChIP-PET) 
(Wei et al., 2006).  The novelty of this technique not only allowed for genome-
wide discovery of transcription factor binding sites but also capitalized on the 
efficiency of sequencing short tags (PET) to reduce background DNA without 
having to undergo further molecular validation.  The DNA fragments that 
generated this dataset were from the colon cancer cell line HCT116 after 
treatment with 5-fluorouracail (5-FU), an antimetabolite.  There were 1,766 PET-
clusters defining genomic loci that represent potential sites of p53 interaction.  
Further analysis established a PET-cluster curve to estimate the level of 
nonspecific versus specific PET clustering events.  Those regions containing 
three or more PETs to a cluster were identified as highly specific for p53 ChIP 
enrichment.   A total of 323 genomic loci had PET-3 clusters and were identified 
as true p53 binding sites.  The ChIP-PET analysis identified binding sites 
upstream of 61% of the previously known p53 target genes (Wei et al., 2006).  
The p53 target gene p21 was found to have a high number of PETs (13) 
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clustered at the known p53 response element.  Of the approximately 100 putative 
target genes associated with the 323 genomic loci, gene ontology analysis 
suggested many novel functions of p53 signaling through these target genes 
including cell adhesion and mobility, ion channel activity, and metabolism. 
In 2008, the first p53 sequential ChIP-on-chip dataset was made available. 
This dataset was generated on a genomic ChIP with probe spacing of 100 bp.  
The DNA used in the hybridization was generated from U2OS cells growth 
arrested after treatment with actinomycin D.  The study identified 1,546 genomic 
binding sites occupied by p53 with a 4% false positive rate (Smeenk et al., 2008).  
In comparison to the previous ChIP-PET dataset discussed, this ChIP-on-chip 
genome-wide study has a similar 69% overlap of p53 genomic binding sites.  The 
ChIP-on-chip screen contained 50% of the same genomic sequences identified 
by the ChIP-yeast screen described above.   
 When comparing these three ChIP-derived datasets, only eight genes 
were common to all including p21 and DDB2 (Table 1).  All three of the ChIP 
datasets were performed in unique cells lines after different types of DNA-
damage, and the methods used to identify p53 sites varied as described above.  
These differences amongst the ChIP datasets explain why only a small subset of 
similar p53 genes was found in common.  Additionally, p53 selectively binds 
regions of the genome dependent on the genotoxic stress encountered that may 
also explain why so few genes were similar to all ChIP datasets.  Overlaying of 
the two genome-wide ChIPs created a shared list of 103 genes (Table 2). 
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Gene Expression Datasets 
To create an extensive collection of gene expression datasets, we used 
microarray datasets from several sources.  The first dataset analyzed was from 
work performed in our laboratory by a previous graduate student, Dr. Kristy 
Schavolt.  By ectopically expressing p53 using adenovirus in normal human 
epidermal keratinocytes as compared to GFP vector control adenovirus, she 
generated a list of approximately 2,000 genes upregulated at least 1.5-fold 
(Schavolt and Pietenpol, 2007).   
Additionally, I analyzed differential gene expression in a p53-inducible cell 
model system that was generated in the laboratory by a previous graduate 
student, Dr. Patty Flatt (Flatt et al., 2000).  The inducible system was generated 
by transfection of pIND and pVgRXR vectors into the H1299 lung carcinoma cell 
line, which lacks detectable, endogenous expression of all p53 family members.  
The addition of ponasterone A caused induction of ectopic p53 and G1 and G2 
cell cycle arrest (Flatt et al., 2000).   
We treated both the parental (p53-null) and HIp53 cell lines with 
ponasterone A for 24 h to induce p53.  The experiment was performed in 
duplicate.  At 24 h, cells were harvested and total RNA was isolated using the 
BioRad Aurum kit.  Samples were submitted to the Vanderbilt Microarray core for 
quality control testing and gene expression analysis using the Affymetrix 
Expression (3ʼ) platform.  The microarray dataset generated was robust given 
that the expression of a number of previously identified target genes (CDKN1A, 
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MDM2, BCLXL, and RPS27L) was increased after p53 induction as compared to 
the control p53-null parental cell line.  Overall, the expression of 624 genes was 
increased 2-fold or greater in a p53-dependent manner after 24 h of ponasterone 
A treatment (Table 3).   
 
Gene ontology analysis and qRT-PCR confirmation of p53-dependent regulation 
of putative target genes  
 
The ChIP and gene expression microarray datasets described above were 
overlaid to create a list of potential p53 transcriptional targets.  To investigate 
functional groupings of these genes based on protein domains and previous 
literature we used Ingenuity Software to perform gene ontology analyses.  As 
would be expected, functional groupings of cell cycle, DNA repair, and cell death 
were found as well as functional categories not well linked to p53 signaling 
including cell-to-cell signaling, cell movement, and cellular metabolism (Figure 4). 
Quantitative real-time PCR analysis was performed in paired sets of RKO 
or HCT116 colorectal cancer cell lines to determine p53-dependent regulation of 
40 putative transcriptional targets identified using the p53 selection criteria.  The 
RKO set includes RKOs expressing a CMV-neo empty vector or RKOs 
expressing the human papilloma virus E6 that binds and degrades p53 with the 
cellular E6a protein (Kessis et al., 1993).  These cells were treated with Nutlin (10 
µM) for 24 h.  This drug disrupts p53:MDM2 binding and causes stabilization of 
p53 (Vassilev et al., 2004).  The set of HCT116 cells includes HCT116 p53 (+/+) 
and (-/-), the latter generated by somatic cell recombination (Bunz et al., 1998).   
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These cells were exposed to ionizing radiation (8 Gy) and RNA was harvested 24 
h later.  We found that 82.5% of the putative transcriptional targets identified 
using our genomic analyses were in fact regulated in a p53-dependent manner 
(Figure 5). 
  
Mathematical Models 
A limiting factor of using microarray based data to analyze target gene 
expression is that the datasets often only include one time point.  Clustering 
methods have attempted to resolve this issue by correlating similar gene 
expression profiles to suggest that a group of genes with similar transcript 
profiles over a timecourse are likely regulated by the same transcription factor. 
The dynamic mathematical model incorporates RNA production and degradation 
terms and prior biological knowledge, using a set of previously established target 
genes, and determines the activity of that transcription factor from microarray 
data (Barenco et al., 2006).  This algorithm ultimately results in a tool that allows 
for the calculation of confidence intervals for each potential transcriptional target 
(Barenco et al., 2006).   
To apply the dynamic mathematical algorithm, the MOLT4 human 
leukemia cell line was irradiated to activate endogenous p53 activity for gene 
expression analysis (Barenco et al., 2006).  A training set consisting of five well-
known target genes including DDB2, p21, Sesn1, BIK, and TNFRSF10b was 
used to derive the p53 activity profile that drives the dynamic  
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mathematical algorithm.  Once applied to gene expression microarray data, a list 
of the top 50 genes transcriptionally regulated by p53 was published and ranked 
according to a sensitivity score.  Additionally, to verify p53-dependent regulation 
gene expression microarray was performed on RNA harvested from MOLT4 cells 
in which p53 was knocked down by siRNA targeting.  Of the p53 target genes 
predicted by the mathematical modeling algorithm, 90% were validated as being 
regulated in a p53-dependent manner based on their sensitivity score to siRNA 
targeting p53.  Twenty-five of the top 50 putative p53 targets were unpublished at 
the time the algorithm was publicly released.  However, since the generation of 
this ranked list in 2006, eight of the remaining 25 have since been published as 
verified p53 targets validating this dynamic mathematical modeling. 
 
p53 Family Overlay 
Work performed by our group shows that despite differences in cell lines 
and methodologies, comparison of p53 family ChIP and gene expression 
microarray datasets showed considerable overlap of putative transcriptional 
targets amongst the family members (Wei et al., 2006; Yang et al., 2006, 
Rosenbluth et al, personal communication).  To begin a p53 family member 
comparison a comprehensive dataset for each p53 family member was selected.  
The p53 genome-wide, ChIP-PET screen described above (Wei et al., 2006),  a 
p63 genome-wide, ChIP-seq (Yang et al., 2006) and a whole genome p73 ChIP 
dataset  (Rosenbluth, personal communication) were chosen.  Each dataset was 
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generated in a different cell line under different conditions.  For p53, ChIP-PET 
methods used in HCT116 cells after treatment with 5-FU identified 1766 sites 
(Wei et al., 2006).  The p63 dataset was generated from a ME180 cervical 
carcinoma cell line with or without actinomycin D treatment  and 5800 binding 
sites were found (Yang et al., 2006).  The p73 dataset was generated in the 
Rh30 cell line after treatment with rapamycin and found 7678 binding sites in 
control compared to 8165 binding sites of p73 after treatment (Rosenbluth, 
personal communication). 
 We further advanced the “p53-focused” collection of transcriptional 
targets with additional cross-comparisons using p63 and p73 ChIP and gene 
expression microarray analyses performed in our laboratory.  Unlike the previous 
overlays where only ChIP results were described, we combined ChIP and gene 
expression analysis to identify putative targets that were bound and regulated by 
the family members.  To further analyze with our set of putative p53 
transcriptional targets, we used p73 and p63 gene expression analyses that were 
performed in our laboratory for comparison.  Both ChIP and gene expression 
microarray analyses were performed with DNA and RNA, respectively, that was 
generated from primary cultures of human mammary (HMEC), skin (NHEK), and 
prostate epithelial cells (HPrEC) expressing nonsilencing or p63 siRNA.  A similar 
approach was taken to identify novel targets of p73 by combining ChIP and gene 
expression microarray in H1299 ectopically expressing TAp73β as well as in the 
Rh30 cells where endogenous p73 activity was evaluated in cells grown in the 
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presence or absence of the mTOR inhibitor, rapamycin (Rosenbluth et al, 
personal communication).   
A list of approximately 212 genes resulted from overlapping the three p53 
family ChIP datasets described above with microarray gene expression datasets 
generated from p53-inducible model systems.  Approximately 23% (48 genes) of 
these genes at the intersection of the ChIP and gene expression datasets have 
been validated and published previously as direct p53 transcriptional targets.  
Further, after overlaying these genes with the p63 and p73 genomic ChIP and 
gene expression datasets described above, we found that six genes were bound 
by all three family members; 17 genes were bound by p53 and p63; and an even 
greater number of 40 genes were bound by p53 and p73 (Figure 6).  Of the 149 
genes uniquely regulated by p53, 31 have been previously published and linked 
to p53 signaling.   
 
Discussion 
 Using a combination of gene expression microarray analyses, ChIP, and 
mathematical modeling methods we identified putative p53 transcriptional targets 
for further functional characterization in the p53 signaling pathway.  Our subset of 
p53 putative transcriptional targets has been further validated since its 
compilation in 2006.  Our group and others have published many genes of 
functional biological significance from our list of p53 targets including RPS27L,  
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GLS2, PRKAB1, LIF, TOB1, PTP4A1/ PRL-1, COMMD1, ANKRD11, LASP1, 
STX6, and ISG20L1. 
Endothelin-2 (EDN2) is one of only five putative p53 target genes, along 
with p21, that was identified in common with the ChIP-yeast, ChIP-PET, and 
inducible-p53 gene expression microarray datasets.  Endothelin-1 and -3 are 
characterized as putative vasoactive peptides (Yanagisawa et al., 1988) and 
chemoattractants during tumor angiogenesis and migration (Stiles et al., 1997) as 
well as melanocyte development and melanoma (Eberle et al., 1999).  Previous 
work in our laboratory identified a strong p53-consensus binding site in EDN2 
located within 2 kb of exon 1 and EDN2 was regulated in a p53-dependent 
manner (Hearnes et al., 2005).  In addition, we found that EDN2 can also be 
regulated by both p63 and p73, depending on cellular context.  A significant 
increase in EDN2 levels occurred during epidermal differentiation (Kotake-Nara 
and Saida, 2006).  In the lung cancer cell line H1299, that lacks expression of the 
p53 family members, ectopic TAp63γ expression led to an approximately 22-fold 
elevation of EDN2 as determined by qRT-PCR.  Corroborating evidence that p63 
contributes to EDN2 regulation was found in HMECs and human prostate 
epithelial cells (HPrECs) when suppression of p63, using an adenovirus targeting 
the DNA binding domain of p63, caused a 60% reduction in the expression levels 
of EDN2.   
The unnamed protein KIAA0247 was identified as a putative p53 
transcriptional target in each of the ChIP datasets mentioned above as well as 
  82 
the p63 and p73 ChIP datasets generated in our laboratory.  KIAA0247 was 
induced greater than 2-fold in our H1299 p53 inducible microarray gene 
expression dataset and ranked as one of the top 50 putative p53 targets by the 
mathematical algorithms.  Induction of p73 expression in the Rh30 cell line  
treated or not with rapamycin, resulted in a greater than 15-fold increase in 
binding of p73 at the KIAA0247 consensus binding site (Rosenbluth et al., not yet 
published).  This gene maps to chromosome 14q24.1 and has an open reading 
frame that encodes a putative 303 amino acid protein of a predicted molecular 
weight of 35 kDa.  Functional domain analysis demonstrated the presence of one 
short consensus repeat domain (CCP/sushi/SCR region).  The consensus repeat 
domain is commonly found in complement genes, often localizing to the cell 
surface, and involved in protein-protein interactions.  In a few instances, the 
presence of this domain is necessary for apoptotic activation (e.g. IL-15R and 
Drs) (Tambe et al., 2004; Wei et al., 2001).  Interestingly, KIAA0247 was 
identified as an induced gene in a p53-temperature sensitive model (Robinson et 
al., 2003).  The authors claimed that KIAA0247 has an AVPI-like motif.  AVPI 
motifs, found in Smac/Diablo proteins, can compete for binding to the BIR3 
domains of XIAPs thereby releasing bound caspases and inducing apoptosis 
(Sun et al., 2007).  The identification of KIAA0247 in an expression dataset 
where apoptosis was induced in a p53-dependent manner is further suggestive of 
its function in cell death (Robles et al., 2001).  Though the potential role of 
KIAA0247 in disease is not yet known, this gene has been found in both lung and 
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ovarian cancer gene expression signatures as a marker of prognosis and 
metastasis, respectively (Dressman et al., 2007; Zhang et al., 2007).  It will be of 
interest to determine if KIAA0247 plays a role in cell death, and if the mechanism 
occurs as suggested by its AVPI motif, where KIAA0247 may bind XIAP thereby 
releasing caspase-9. 
The gene ISG20L1/FLJ12484/AEN was identified in the ChIP-yeast 
selection method with a p53 consensus binding site located within one kb of the 
transcriptional start site (Hearnes et al., 2005).  This same p53 consensus site 
was identified in the ChIP-PET sequencing analysis with three overlapping PETs 
indicating increased likelihood of p53 binding (Wei et al., 2006), and is the most 
highly ranked p53 consensus binding site found using the computer algorithm 
p53MH (Hoh et al., 2002).  ISG20L1 is transcriptionally upregulated across 
numerous cell types including lung, breast, hematopoietic, and colon cell lines 
after treatment with genotoxic stresses such as ionizing radiation, as well as after 
encountering the inflammatory stresses NO, H2O2, and hypoxia (Barenco et al., 
2006; Hearnes et al., 2005; Staib et al., 2005; Sun et al., 2005; Wei et al., 2006).  
The functional role of IGS20L1 downstream of the p53 family will be further 
explored in Chapter IV of this dissertation. 
The identification of p53 transcriptional targets is central to further 
understanding of the functional signaling downstream of this tumor suppressor 
gene in both normal and disease states.  We have used a number of criteria to 
create a subset of p53 putative transcriptional targets for further functional 
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characterization including presence in ChIP datasets, gene expression analyses, 
and ranking in p53 mathematical algorithms. Functional characterization of one of 
these target genes, ISG20L1, is presented in detail in Chapter IV of this 
dissertation.  
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CHAPTER IV 
 
 
 
ISG20L1 IS A P53 FAMILY TARGET GENE THAT MODULATES GENOTOXIC 
STRESS-INDUCED AUTOPHAGY 
 
 
 
Introduction 
 
p53 can regulate autophagy in both a transcriptionally-dependent and -
independent manner (Crighton et al., 2006; Feng et al., 2007).  Autophagy is a 
mechanism used by cells to maintain metabolic homeostasis in the biological 
context of starvation (Komatsu et al., 2005).  During starvation, cells form double 
membrane autophagosomes that engulf cellular contents for degradation and 
these vesicles recycle the basic metabolic components for consumption (Levine, 
2005).  Although originally thought to be primarily induced to promote cell survival 
during starvation, autophagy also occurs after various forms of genotoxic stress 
and plays a role in cell death (Green and Chipuk, 2006; Kang et al., 2007; Scott 
et al., 2007; Shimizu et al., 2004). p53 has a dual role in autophagy and the 
molecular mechanisms are only now being discerned (reviewed in (Green and 
Kroemer, 2009; Levine and Abrams, 2008)).  Basal levels of cytoplasmic p53 
repress autophagy in a transcriptionally-independent manner (Tasdemir et al., 
2008).  Depletion of p53 or pharmacological inhibition using pifithrin-α causes 
induction of autophagy (Tasdemir et al., 2008).   The transcriptional dependent 
mechanisms of nuclear p53 are more widely described in connection of p53 and 
autophagy.  Nuclear p53 stimulates autophagy through transactivation of target 
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genes such as Sestrins, TSC2, and DRAM (damage-regulated autophagy 
modulator) (reviewed in (Vousden and Ryan, 2009)).  Under conditions of 
genotoxic stress such as ionizing radiation or camptothecin treatment, p53 
upregulates the AMPK activators Sestrin1 and Sestrin2 that will ultimately induce 
autophagy through the inhibition of mTOR (Braunstein et al., 2009; Budanov and 
Karin, 2008).  Upregulated by various stress signals including DNA damage, 
DRAM is a transcriptional target of p53 that is lysosomal in location and required 
for p53-induced autophagy, although the mechanism by which DRAM regulates 
autophagy is currently unknown (Crighton et al., 2006).  
p63 and p73 are two p53 homologs that share similar structure and have 
both unique and coordinate roles during development and tumorigenesis 
(Murray-Zmijewski et al., 2006).  The signaling upstream of each p53 family 
member is dependent on cellular context and various regulatory mechanisms 
[reviewed in (Rosenbluth and Pietenpol, 2008)].  Recently, work from our 
laboratory has shown that in addition to the interplay of mTOR and p53, inhibition 
of mTOR activates p73 and results in p73-dependent modulation of genes 
involved in metabolism and autophagy (Rosenbluth and Pietenpol, 2008; 
Rosenbluth and Pietenpol, 2009).  Though p73 also transcriptionally regulates 
the p53 target gene DRAM, p73-dependent autophagy does not require DRAM 
(Crighton et al., 2007). 
As presented in Chapter III, we have identified numerous, novel candidate 
p53 target genes by overlaying ChIP and gene expression datasets (Hearnes et 
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al., 2005; Schavolt and Pietenpol, 2007).  Of interest was the discovery of 
ISG20L1, a gene that was named due to its significant similarity with ISG20L2, a 
nucleolar protein that functions in the processing of the 5.8S rRNA (Coute et al., 
2008).  To determine the role that ISG20L1 plays in p53 family signaling, we 
generated an ISG20L1-specific antibody, analyzed ISG20L1 regulation by all 
three members of the p53 family, and functionally linked ISG20L1 to genotoxic 
stress-induced autophagy. 
 
Results 
ISG20L1 Antibody Production 
 The human ISG20L1 gene is 3.1 kb and evolutionarily conserved with 
72% identity to M. musculus.  We generated a rabbit polyclonal antibody to the 
human ISG20L1 protein (UniProt Q8WTP8) using a 15 amino acid sequence 
(HGSRGGAREAQDRRN) located at the C-terminus of the protein outside of the 
exonuclease III domain; database searching confirmed that this peptide is unique 
to ISG20L1.  We performed Western analyses in conjunction with gene 
overexpression and knockdown assays, to determine that our newly developed 
antibody could specifically identify a protein of the predicted molecular weight 
(~37 kD).  For overexpression analyses, protein lysates were prepared from 
H1299 cells engineered to ectopically express FLAG-tagged human ISG20L1.  
RNA knockdown experiments were performed in H460 cells by reverse 
transfecting siRNAs directed against ISG20L1 and subsequently treating with 
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ionizing radiation to upregulate endogenous ISG20L1 protein levels (Figure 7a).  
The antibody we produced had specificity for ISG20L1, the levels of which were 
significantly reduced after siRNA knockdown or enhanced with ectopic 
expression of ISG20L1, respectively (Figure 7a).  These results are the first 
demonstration of detection and regulation of endogenous ISG20L1 protein. 
Having confirmed antibody specificity, we analyzed the cellular localization 
of ISG20L1 in H1299 cells ectopically expressing a FLAG-tagged ISG20L1.  
Immunofluorescence analyses showed nuclear localization of ectopically 
expressed ISG20L1, similar to the staining pattern seen using a FLAG antibody 
(Figure 7b).  Merging nuclear DAPI staining with ISG20L1-specific staining, 
showed ISG20L1 localizes to a region of the nucleus having decreased density 
identified as the nucleolus and higher magnification analyses confirm increased 
intensity at perinucleolar regions (Figure 7b).  Although detectable by Western, 
we were unable to identify endogenous ISG20L1 using immunofluorescence. 
 
p53 Family Regulation of ISG20L1 
To analyze p53 regulation of ISG20L1 we used primary cultures of normal 
human keratinocytes (NHEKs), a model system with intact p53 signaling (Flatt et 
al., 1998; Schavolt and Pietenpol, 2007).  NHEKs were infected with control  
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shRNA or shRNA targeting p53 and exposed for 6 h to cisplatin to elevate p53 
activity.  Western analysis showed that both p53 and ISG20L1 protein levels 
were elevated after cisplatin treatment and this increase was primarily p53-
dependent as the shRNA targeting p53 significantly decreased the cisplatin-
induced elevation in p53 and ISG20L1 protein levels (Figure 8).  We hypothesize 
that residual ISG20L1 expression was due to cisplatin-mediated elevation of 
TAp73 activity or protein as previously shown (Agami et al., 1999; Gong et al., 
1999; Lapi et al., 2006; Yuan et al., 1999).  However, p73 protein is difficult to 
detect in primary cultures of normal human keratinocytes, likely due to the low 
level of expression in normal cells (Schavolt and Pietenpol, 2007). 
Given the residual expression of ISG20L1 in p53-depleted keratinocytes 
(Figure 8) and the overlapping binding and activity of p53 family members at 
many regulatory regions in the genome, we hypothesized that ISG20L1 is also 
regulated by p63 and p73.  To test this hypothesis, we transfected 293FT cells 
with plasmids encoding the transcriptionally active isoforms of the p53 family 
(p53, TAp73β, and TAp63γ) as well as the transcriptional repressor ΔNp63α.  
These cells express low levels of TAp73, non-detectable p63, and wild-type p53 
that is stabilized and inactivated by association with E1A and large T antigen 
(see pCEP4 control lane of Figure 9b).  Twenty-four h after transfection, we 
isolated RNA and protein and analyzed ISG20L1 by qRT- PCR and Western, 
respectively.   ISG20L1 levels were increased approximately 2-fold or more by  
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p53, TAp73β, and TAp63γ while ΔNp63α expression decreased levels of 
ISG20L1 as seen at both the mRNA and protein level (Figure 9a and 9b).  
Noting the elevation of ISG20L1 after TAp73 expression, we analyzed the 
ability of endogenous TAp73 to regulate ISG20L1 using the Rh30 
rhabdomyosarcoma cell line.  Rh30 cells do not express p63 and contain mutant 
p53, thereby allowing us to investigate the endogenous regulation of ISG20L1 
solely by p73.  We treated cells with paclitaxel or cisplatin, two agents known to 
increase p73 activity (Leong et al., 2007; Oh et al., 2008), and observed an 
elevation in TAp73 protein levels that were accompanied by an increase in 
ISG20L1 expression (Figure 10a).  Elevation of ISG20L1 was TAp73-dependent 
as shRNA depletion of TAp73 eliminated ISG20L1 expression after treatment 
(Figure 10a, right panel).  To verify p73-dependent regulation was not cell-type or 
damage specific, we infected MDA-MB-231, cells that are also lacking p63 and 
mutant for p53, with a shRNA lentivirus targeting p73 and treated with rapamycin, 
an agent known to elevate p73 activity in this cell line (Rosenbluth et al., 2008).  
Rapamycin is an inhibitor of the TOR pathway that regulates cell growth and cell 
cycle progression based on nutrient-dependent signaling and thus rapamycin has 
similar effects as nutrient starvation (Peng et al., 2002).  ISG20L1 RNA levels 
were decreased ~50% by RNAi knockdown of p73 and rapamycin treatment 
resulted in a greater than 2-fold induction in ISG20L1 expression that was 
abrogated with p73 knockdown (Figure 10b).  Thus, ISG20L1 can be modulated  
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by various forms of cell stress (genotoxic and metabolic), and in the absence of 
p53 its expression is dependent on other p53 family members.  
 Next we explored the ability of the p53 family members to bind the 
ISG20L1 promoter region.  Previous findings suggest that the p53 family 
members have similar transcription factor binding domains, but p53 and p63 
have different affinities due to slight differences in consensus site sequence 
composition and co-factor binding sites present in the promoter regions of 
regulated genes (Ortt and Sinha, 2006; Perez et al., 2007; Shikama et al., 1999; 
Zhu et al., 1998).  The p53 binding site discovered by our previous ChIP-based 
screen, CCACATGCCC-0-GGGCAAGCCC, was located approximately 450 bp 
upstream of the ISG20L1 transcriptional start site and matches the p53 canonical 
binding site at 18 of 20 base pairs, with no spacer in the palindrome (Hearnes et 
al., 2005).  To determine if p53 and p63 bind and regulate ISG20L1 at the same 
promoter region, we used human mammary epithelial cells (HMECs) that express 
p53 and p63 at levels sufficient for chromatin analyses (Perez et al., 2007).   
HMECs were chemically crosslinked under control and cisplatin-treated 
conditions, the latter agent can regulate the p53 signaling axis (Fritsche et al., 
1993; Leong et al., 2007).  Chromatin was prepared and immunoprecipitated with 
antibodies to p53, p53-Ser15, p63, and a negative control antibody against a 
non-DNA binding protein (Venter et al.).   Primers were used to amplify the region 
of the ISG20L1 gene previously reported to contain the p53 binding site (Hearnes 
et al., 2005).  Chromatin immunoprecipitation analysis (ChIP) showed increased 
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binding of p53 and p53-Ser15 after cisplatin treatment, and p63 bound the 
promoter region of ISG20L1 under both control and cisplatin treated conditions 
(Figure 11a).  These data indicate that both family members cooperate to 
regulate ISG20L1 expression.  
Given that HMECs do not express levels of p73 sufficient for chromatin 
analysis we performed p73 ChIP in the Rh30 cells to assess p73 binding levels 
at the ISG20L1 promoter in response to rapamycin treatment.  After rapamycin 
treatment, p73 binding at the p53 consensus binding site in the ISG20L1 
promoter increased ~15-fold as compared to a vehicle only-treated control 
(Figure 11b).  Collectively, these data show that all three p53 family members 
can bind to the promoter region of ISG20L1 and regulate its gene expression. 
 
ISG20L1 and Cell Death 
Shortly after our discovery of ISG20L1 as a p53 target (Hearnes et al., 
2005), ISG20L1 was reported to have exonuclease function in vitro (Lee et al., 
2005) prompting us to determine if it played a role in DNA laddering during the 
execution phase of apoptosis.  Using siRNA knockdown, we decreased ISG20L1 
levels in RKO cells and treated with 5-fluorouracil (5-FU) to induce apoptosis.  
Neither knockdown of ISG20L1 nor 5-FU treatment after knockdown affected the 
onset or extent of apoptosis as measured by analyses of PARP and caspase-3 
cleavage, sub-G1 content quantified by flow cytometry, and DNA laddering   
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(Figure 12a and 12b).  These data suggest that ISG20L1 does not play a role in 
the execution phase of apoptosis. 
To determine if ISG20L1 plays a role in genotoxic stress-induced 
autophagy we analyzed the effect of ISG20L1 modulation (ectopic expression or 
knockdown) in RKO cells after etoposide, a treatment that induces autophagy.  
During autophagy an ubiquitin-like signaling cascade is initiated that results in 
cleavage of a protein essential for autophagy, microtubule associated-protein 1 
light chain 3 (MAP1LC3) (reviewed in (Cecconi and Levine, 2008)).   After 
cleavage and post-translational modification (lipidation), MAP1LC3 (LC3-II) 
associates with autophagosomal membranes (Kabeya et al., 2000), and this 
modified form of LC3-II is used as a reliable molecular marker of autophagy 
(Klionsky et al., 2008).  We reverse transfected RKO cells with control or 
ISG20L1 siRNA and treated with etoposide.  Etoposide treatment resulted in a 
considerable increase in both ISG20L1 and LC3-II protein levels (Figure 13a).  
Robust knockdown of ISG20L1 resulted in a significant reduction in LC3-II as 
measured by Western (Figure 13a, right panel) and an ~70% reduction in LC3 
positive cells as measured by immunohistochemistry (IHC) using an antibody that 
detects endogenous, cleaved LC3 (Figure 13b and 13c).   To assess if 
knockdown of ISG20L1 was modulating autophagy flux, we added protease 
inhibitors, E64d and pepstatin A, to inhibit lysosomal degradation and LC3-II 
turnover (Klionsky et al., 2008).  RKO cells were treated with etoposide and 
lysosomal inhibitors for 8 h, three days after reverse transfection with control or  
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ISG20L1 siRNA.  Under these conditions, knockdown of ISG20L1 decreased 
LC3-II levels and thus autophagic flux (Figure 14a).  We investigated if ectopic 
expression of ISG20L1 affected autophagy and transfected RKO cells with vector 
control (pCEP4) or pCEP4 expressing ISG20L1.  RKO cells ectopically 
expressing ISG20L1 showed an increase in LC3-II by Western analysis (Figure 
14b).  
To verify these results were not cell type-, damage-, or assay-specific 
U2OS cells were transfected with control siRNA or three unique siRNAs that 
target ISG20L1 with varying degrees of knockdown.  After treatment with 5-FU, 
LC3-II levels decreased in a dose-dependent manner relative to levels of 
ISG20L1 knockdown (Figure 15).  We further determined that knockdown of 
ISG20L1 in U2OS cells treated with 5-FU does not alter cell cycle distribution 
(Figure 16).   
Autophagy was first studied and quantified using electron microscopic 
(EM) detection of autophagosomes (Klionsky et al., 2008; Mizushima, 2004; 
Mizushima et al.).  To verify that the modulation of LC3-II observed in 5-FU 
treated U2OS cells was a reliable marker of autophagy, we performed EM on 
parallel cultures of U2OS cells expressing either control siRNA or the siISG20L1-
1 and representative electron micrographs are shown (Figure 17).   Morphometric 
analysis (Swanlund et al.; Yla-Anttila et al., 2009) showed an approximately 6-
fold decrease in the percentage of autophagic vacuole volume fraction after  
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knockdown of ISG20L1 (Figure 17, p<0.0001, n = 25 cells, duplicate 
experiments).    
As described in the previous section, after autophagy induction, lipidated 
LC3-II is associated with autophagosomal membranes, resulting in the formation 
of punctate foci that can be quantified by fluorescence microscopy (Kabeya et al., 
2000; Klionsky et al., 2008).  To assess autophagy flux in the U2OS cell system, 
we used a LC3 (mRFP-GFP-LC3) vector that generates a LC3 fusion protein 
tagged at the 5ʼ end with red fluorescent protein (RFP) and green fluorescent 
protein (GFP).  Expression of mRFP-GFP-LC3 allows the distinction between 
early autophagic organelles (dual RFP+GFP+ puncta) and mature, acidified 
autolysosomes (RFP+ GFP- puncta) as the GFP signal is quenched in acidic 
compartments (Kimura et al., 2007 2008; Klionsky et al., 2008).  U2OS cells 
stably expressing mRFP-GFP-LC3 were transfected with control or ISG20L1 
expressing vectors and treated with 5-FU for 24 h. Those cells ectopically 
expressing ISG20L1 had a greater number of total LC3 foci and a 2.6-fold 
increase in the percentage of (RFP+GFP-) LC3 puncta per cell representing an 
increase in maturing autophagosomes (Figure 18, p<0.001, n = 50 cells; yellow 
arrows represent early autophagosomes that are RFP+GFP+, white arrows 
indicate late autolysosomal foci that are RFP+GFP-).  These data show that 
ISG20L1 affects autophagy flux through autophagosome formation and 
maturation into autolysosomes.  
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To extend and translate our mechanistic findings to the biologically 
relevant endpoint of cell growth, we analyzed the effect of ISG20L1 expression 
using colony formation assays.  We transfected RKO, H1299, HCT116 cells as 
well as ATG5+/+ and ATG5-/- mouse embryonic fibroblasts (MEFs) with control or 
ISG20L1 expression vectors, selected the cells in hygromycin for 10 days, and  
measured clonogenic growth.  ATG5-/- MEFs were derived from an ATG5-null 
mouse model system and shown to be autophagy defective (Kuma et al., 2004).   
A representative result from one of the tumor-derived cell lines (HCT116) 
is presented in Figure 19.  Cells ectopically expressing ISG20L1 had a 48% 
reduction in colony formation as compared to those cultures expressing an empty 
vector control.   Parallel flow cytometric analyses were performed at 48, 72, and 
96 h after transfection and no differences were observed in sub-G1 DNA content 
or Annexin V staining, between control and ISG20L1 expressing cells (Figure 20 
and 21).  Use of the ATG5+/+ and ATG5-/- MEFs enabled us to determine if the 
decreased clonogenic survival after expression of ISG20L1 was dependent on 
ATG5-induced autophagic processes.  As observed in the human cell lines, 
ectopic expression of ISG20L1 in the ATG5+/+ MEFs decreased colony number 
by ~77% compared to control.  Importantly, this ISG20L1-induced decrease in 
colony number was partially rescued in ATG5-/- cells (over 2-fold increase; Figure 
22).  Collectively, these data are consistent with a function for ISG20L1 in 
genotoxic stress-induced autophagy and decreased cell survival.  
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Discussion 
  Several studies provide evidence for a role of p53 in autophagy, a 
process first recognized as important in cell survival and now thought to function 
in tumor suppression (Crighton et al., 2006; Feng et al., 2005; Yue et al., 2003).  
We strengthen this link between the p53 signaling axis and genotoxic-stress 
induced autophagy by identifying ISG20L1 as a transcriptional target of all three 
p53 family members.  Using a newly generated antibody, we show that ISG20L1 
levels increase in a p53- and TAp73-dependent manner after various forms of 
stress.  In addition to p53, the family members p63 and p73 can bind and directly 
regulate ISG20L1 expression.  Ectopic expression of ISG20L1 decreased cell 
survival without induction of apoptosis as determined by flow cytometric analyses 
of sub-G1 DNA content or Annexin V staining, and the decreased clonogenic 
survival was partly rescued in an autophagy deficient background (ATG5-/- 
MEFs).   ISG20L1 was not involved in modulating 5-FU-mediated apoptosis, as 
suppression of ISG20L1 in RKO cells did not alter the incidence or extent of 
apoptosis as measured by PARP and caspase-3 cleavage, sub-G1 content, and 
DNA laddering.  In contrast, siRNA knockdown of ISG20L1 decreased genotoxic 
stress-induced autophagy as measured by electron microscopy, biochemical, 
and immunohistochemical analyses of LC3-II.  Thus, we identified ISG20L1 as a 
p53-family dependent, genotoxic stress-induced modulator of autophagy. 
The nucleolus is the cellular site of rRNA synthesis and processing as well 
as ribosomal assembly (Scheer and Hock, 1999).   One of the first connections of 
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p53 to nucleolar signaling was the observation that a dominant-negative form of 
the nucleolar protein Bop1 could induce p53-dependent cell cycle arrest (Pestov 
et al., 2001).  Recent publications have linked nucleolar proteins to arbitrating 
cellular response to stress, including autophagy (David-Pfeuty, 1999; Olson, 
2004; Rubbi and Milner, 2003). For example, nucleolar ARF can inhibit the 
production of the immature 12S rRNA intermediate, interact with the 5.8S rRNA 
(Sugimoto et al., 2003), and activate autophagy in p53-positive cells (Abida and 
Gu, 2008).   
Our data validates previous findings of ISG20L1 nucleolar localization 
(Kawase et al., 2008; Lee et al., 2005).  ISG20L2, a family member of ISG20L1, 
also localizes to the nucleolus and is involved in the processing of 12S rRNA to 
the mature 5.8S rRNA, part of the large ribosomal subunit (Coute et al., 2008).  In 
vitro assays have shown that the exonuclease III domain of ISG20L1 is required 
to degrade single- and double- stranded DNA and RNA (Kawase et al., 2008; 
Lee et al., 2005).  Collectively, the recent findings that ISG20L1 can degrade 
RNA, our data and others showing nucleolar localization of ISG20L1, and our 
linkage of ISG20L1 to autophagy suggests it will be important to examine the role 
of ISG20L1 in rRNA processing and ribosomal assembly during cellular response 
to stress (Kawase et al., 2008; Kraft et al., 2008; Lee et al., 2005). 
There is growing evidence for the interplay between autophagy and the 
p53 family.  As mentioned above, p19ARF and the short mitochondrial form 
(smARF) are able to induce autophagy in both p53-dependent and –independent 
  115 
manners (Abida and Gu, 2008).   A number of genes involved in autophagy are 
directly regulated by p53 including the mTOR inhibitors, TSC1 and PTEN, 
Sestrin1 and Sestrin2, and the damage-regulated autophagy modulator (Venter 
et al.) (Crighton et al., 2006; Feng et al., 2005).  Additionally, inhibition of mTOR 
by p53 is associated with autophagy and occurs through DNA damaged-induced 
signaling involving AMPK and TSC1/2 (Feng et al., 2005).  p73 transcriptional 
activity has also been linked to autophagy as p73 is bound to a number of genes 
involved in metabolism and autophagy (Crighton et al., 2007; Rosenbluth and 
Pietenpol, 2009).  Our results show that ISG20L1 is contributing to cellular 
demise by modulating the process of autophagy that is commonly associated 
with type II cell death (Bursch et al., 2008; Eisenberg-Lerner et al., 2009).  
 The identification of ISG20L1 as a p53 family target and discovery that 
modulation of this target can regulate autophagic processes further strengthens 
the connection between p53 signaling and autophagy.  Given the keen interest in 
targeting autophagy as an anticancer therapeutic approach in tumor cells that are 
defective in apoptosis, investigation of genes and signaling pathways involved in 
cell death associated with autophagy is critical.  
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 
 
 p53 is the most frequently mutated gene in human cancer (Baker et al., 
1989; Daujat et al., 2001; Momand et al., 2000; Nigro et al., 1989).  As a 
transcription factor, p53 regulates a multitude of genes involved in cell cycle 
progression (el-Deiry et al., 1994), genomic stability (Tanaka et al., 2000), cellular 
senescence (Shay et al., 1991), apoptosis (Oda et al., 2000b), angiogenesis 
(Ravi et al., 2000), cell migration (Gadea et al., 2002), and autophagy (Crighton 
et al., 2006).  The transcriptional activity of p53 is required for its tumor-
suppressor ability (Pietenpol et al., 1994).  The goal of this dissertation was to 
identify novel p53 family transcriptional targets and determine their functions in 
biologically-relevant processes downstream of the p53 family signaling axis. 
  
Identification and characterization of p53 family target genes 
Our experience has shown the false discovery rate to be high when only 
using a single assay (i.e. ChIP or microarray analysis) to identify p53-bound or 
regulated genes.  Given this observation, along with the public availability of a 
vast array of p53 datasets, we overlaid numerous genomic datasets from both 
ChIP and gene expression assays to identify a subset of high-confidence putative 
p53 target genes.  The generation of our gene list is described in Chapter III of 
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this dissertation, and includes a number of previously published p53 target 
genes, such as p21 and MDM2.   
We utilized a number of criteria to create a panel of putative p53 
transcriptional targets.  To identify those genes that were directly bound and 
regulated by p53, we analyzed three unique ChIP datasets that provide ~1,600 
predicted p53 binding sites (Hearnes et al., 2005; Smeenk et al., 2008; Wei et al., 
2006).  Since presence of a p53 binding site in a gene does not always equate to 
transcriptional regulation, we also performed gene expression microarray 
analyses on RNA isolated from an inducible p53 cell model system that 
undergoes p53 mediated arrest.  When compared to the p53 null-parental cell 
line, induction of p53 resulted in upregulation of 624 genes two-fold or greater.  
Additionally, we used a gene expression dataset generated previously in our 
laboratory from primary human keratinocytes engineered to ectopically express 
p53 (Schavolt and Pietenpol, 2007).  After combining ChIP and gene expression 
data, the last tool used in the identification of new p53 transcriptional targets was 
a mathematical algorithm that ranks the probability of a gene being a putative 
transcriptional target based on gene expression data (Barenco et al., 2006).   
Since the generation of our putative p53 target gene collection, 10 genes 
have been published by our laboratory and others.  For example, we identified 
the ribosomal gene RPS27L as a novel p53 target gene.  During our 
characterization of RPS27L, another laboratory published it as a p53 target gene 
that regulates apoptosis (He and Sun, 2007; Li et al., 2007).  Gene ontology 
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analyses show that a number of the identified p53 target genes function in 
multiple pathways governed by p53, such as cell cycle regulation, DNA repair, 
and cell death.  In addition, other genes in our subset are identified as being 
involved in processes novel to p53 signaling including cell-to-cell signaling, cell 
morphology, and cellular metabolism.  Given this, we anticipate that our future 
analyses will not only discover target genes that function in canonical p53 
signaling pathways, but may ultimately reveal completely novel signaling 
mechanisms regulated by p53 itself. 
 Early studies aimed at identifying p53-regulated genes often involved 
analyzing a single gene, in a single p53-regulated process, such as apoptosis.  
Though these studies provided an enormous wealth of information with regards 
to p53 function, the “single-gene-single-assay” approach can often be laborious 
and time-consuming.  The advancement in genomic technologies makes possible 
the study of multiple genes in a high-throughput manner, using assays based on 
gene depletion and/or exogenous expression.  With my panel of numerous 
putative p53 target genes and new genomic and molecularly-based technologies, 
our future plans for this project include a high throughput siRNA loss-of-function 
screen to identify the contribution of these genes to biological processes 
regulated by p53.  A high throughput analysis of genes will allow for more rapid 
characterization of novel target genes associated with p53-regulated cellular 
functions, such as cell cycle arrest, apoptosis, and autophagy, to name a few.   
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Loss-of-function screens are now routinely used to identify genes and 
pathways, that when targeted, sensitize tumor cells to various drugs.  The 
majority of siRNA screens existing in the literature, test for a single biological 
endpoint or are investigating the identification of genes involved in a single 
pathway.  For example, a recent study by a Vanderbilt graduate student, Dr. 
Courtney Lovejoy, involved a loss of function screen using siRNA in human cells 
to identify genes that when downregulated lead to a DNA damage response as 
measured by the DNA damage marker H2AX-phosphorylation (Lovejoy et al., 
2009).  This screen identified 73 novel genes that when silenced activated the 
DNA damage response pathway.  p53 is involved in numerous cellular pathways 
and these loss-of-function screens now afford us the opportunity to study the 
complexity of p53 signaling by characterizing novel target gene functions in a 
high-throughput manner using assays that cover a wide range of biological 
endpoints including DNA repair, apoptosis, cell survival, migration, and 
autophagy. 
 The subset of p53 family target genes described in detail in Chapter III are 
currently being assayed in siRNA loss-of-function screens.  We have Dharmacon 
OnTarget pools of siRNA that consist of four individual siRNAs all targeting the 
same gene.  A total of 164 genes are being assayed in a microtiter plate format.  
The biological assays that will be performed were chosen either due to prior 
linkage of p53 signaling to the biological endpoint being assayed or based on 
gene ontology analysis. The biological assays are measuring (i) changes in cell 
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number (Alamar blue, Invitrogen); (ii) apoptosis (Caspase-Glo 3/7 assay, 
Promega); (iii) DNA damage and repair (KAP1 immunofluorescence); (iv) 
autophagy (Monodansylcadaverine cell kit, Cayman Chemicals); and (v) 
migration (Oris Pro Cell Migration Assays, Platypus Technologies).  Positive hits 
will be screened in secondary validation assays using two individual siRNA from 
Qiagen.  For example a positive hit from the KAP1 DNA damage screen will be 
tested for H2AX-phosphorylation, and a positive hit in the migration screen will be 
tested in larger format using a scratch assay.  For those genes identified as 
overlapping with the other p53 family members, p63 or p73, we may add 
additional screens with biologically relevant end assays such as keratinocyte or 
human mesenchymal stem cell differentiation.     
  To determine p53-dependence, nonsilencing or siRNA targeting p53 will 
be used in combination with siRNAs targeting the genes under investigation to 
determine if biological effects of target gene knockdown are p53-dependent.  
Appropriate controls will be used to perform our loss-of-function screen.  Controls 
include four individual nonsilencing siRNAs that allow normalization across the 
plates.  Positive controls will be included that are appropriate to the biological 
endpoint being examined, for example siRNA targeting caspase-3 will be used 
for the cell death, Caspase-GLO 3/7 assay.  We are performing these functional 
screens in primary human mammary epithelial cells (HMECs).  These cells were 
selected based on the p53 family member expression status where HMECs 
express all of the family members.  The transfection conditions have been 
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optimized for maximum efficiency of siRNA uptake.  The siRNA screen is 
performed by reverse transfecting the HMECs using a preoptimized cell number 
with siRNA oligos targeting the genes of interest.  Each functional experiment is 
performed in triplicate to allow for statistical analysis.  Three days after reverse 
transfection, each cell line is treated with the IC50 of cisplatin, a DNA intercalator, 
known to activate the various members of the p53 family (Fomenkov et al., 2004; 
Toh et al., 2004).  The duration of treatment depends upon the biological 
endpoint being assayed.  
With the number of putative transcriptional targets growing, we can no 
longer characterize all these genes on an individual basis.  A more high-
throughput siRNA screening method is the only practical approach for initial 
characterization to inform us which target genes should receive more in depth 
and detailed investigation for the role played downstream of the p53 family 
signaling pathway. 
 
Unanswered Questions in the p53 field 
In addition to regulating mRNA expression, p53 also regulates the 
expression of noncoding RNA.  Noncoding RNAs (ncRNAs) include miRNAs that 
are short 22 nucleotide long ribonucleic acid molecules and act as post-
transcriptional regulators by binding to 3ʼ-untranslated regions of the mRNA 
transcript thus targeting it for degradation (Bartel, 2009).   
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Preliminary studies have begun to uncover the interplay of the p53 family 
and miRNAs.  ChIP analyses of p53 binding have shown perfect matches for the 
p53 consensus site and binding at genomic loci that are not located near coding 
regions invoking the question of p53 function at these locations (Hearnes et al., 
2005; Wei et al., 2006).  A number of publications have suggested a connection 
between the miRNA-34 family (miRNA-34a, -34b, -34c) and p53.  The miRNA-34 
family is induced after DNA damage in a p53-dependent manner (Bommer et al., 
2007; Chang et al., 2007; Corney et al., 2007; Tazawa et al., 2007).  p53 
consensus binding sites were found in the two transcripts encoding miRNA-34a 
and miRNA-34b/c (Wei et al., 2006).  Ectopic expression of miRNA-34 family 
induced similar results of G1 cell cycle arrest, inhibition of proliferation, and 
decreased clonogenic cell survival (Bommer et al., 2007; Tazawa et al., 2007).  
Recently, work performed in our laboratory has also found a direct connection 
between p73 and miRNA.  p73 binds 116 miRNAs and  expression levels of 142 
miRNAs changed greater than 50% after p73 knockdown (Rosenbluth et al, 
personal communication).   
Given the connections between the p53 family and direct regulation of 
miRNAs, a number of important questions remain in this field.  As transcription 
factors, p53 family members have previously been assayed for their ability to 
regulate target gene expression and now it will be important to investigate if 
regulation of transcriptional targets occurs directly by p53 or through secondary 
effects after induction of the miRNA-34 family.  It will be necessary to further 
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analyze miRNA-34 alterations in cancer and how restoration of miRNA-34 
function could potentially be used as an anti-cancer therapeutic.  Additionally, it 
will be important to discover other miRNAs controlled by the p53 family.  Since 
the connection between miRNA-34 and p53, only two other miRNA-145 and 
miRNA-192 have published evidence for p53-dependent regulation (Sachdeva et 
al., 2009; Song et al., 2008).  MicroRNA expression arrays obtained from three 
different models including an inducible p53 cell line, a p53 isogenic cell line 
HCT116 treated with DNA-damaging agents, and a conditional p53 model 
suggest that many miRNAs are both up- and down-regulated in a p53-dependent 
manner (Chang et al., 2007; Tarasov et al., 2007).  Future research is required to 
characterize these miRNA and their subsequent targets downstream of p53 
signaling.  Experiments that would yield light on this topic would be a comparison 
of gene expression arrays after knocking down p53, miRNA-34, or p53 and 
miRNA-34 to determine the necessity of miRNAs in p53 transcriptional activities.  
This type of experiment would show if miRNA-34 expression can downregulate a 
specific subset of p53-regulated genes and if p53 requires miRNA for 
transcriptional regulation of certain target genes.     
 
p53 and autophagy: paradoxical signaling 
Numerous transcriptional targets of p53 function in cell cycle arrest or 
apoptosis.  As we discover more novel target genes, new roles for p53 in various 
biological processes are being described, including p53 in the regulation of 
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autophagy.  Autophagy is a recycling process of cellular catabolism that allows a 
cell to breakdown cytoplasmic components for reuse by the cell.  Initially, 
autophagy was discovered after induction by starvation where electron 
microscopy captured the formation of the characteristic double membrane 
autophagosomes that enveloped portions of the cellʼs cytoplasm (De Duve and 
Wattiaux, 1966).  These autophagosomes proceed to fuse with lysosomal 
compartments of the cell where degradative enzymes such as cathepsins 
degrade the macromolecules contained within the autophagolysosome (Berg et 
al., 1998).  Since the discovery of this process in 1966, autophagy has been 
implicated in a number of different normal and disease states.  The importance of 
autophagy has also been seen in the development of higher eukaryotes where 
mice lacking the essential autophagy component Beclin1 die during 
embryogenesis and ATG5- or ATG7-null mice die perinatally (Kuma et al., 2004; 
Yue et al., 2003).  A number of disease states and pathologies are also attributed 
to the process of autophagy including neurodegenerative diseases (Huntingtonʼs, 
Alzheimerʼs, Parkinsonʼs); antiviral and antimicrobial immunity; and cancer.   
p53 activated under DNA-damage and metabolic stress conditions is also 
a known regulator of autophagy (Crighton et al., 2006; Feng et al., 2005; 
Tasdemir et al., 2008).  p53 can both positively and negatively regulate 
autophagy in a transcriptionally-dependent and –independent manner 
respectively.  Inhibition of autophagy is suggested to occur by low levels of 
cytoplasmic transcriptionally-independent functions of p53.  The more widely 
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described role of p53 in autophagy is through the transcription-dependent 
induction of autophagic activity following cellular stress.   p53 can regulate the 
upstream activators of AMPK, Sestrin1 and Sestrin2, after genotoxic and 
oxidative stress, to induce autophagy (Budanov and Karin, 2008).  Outside of the 
mTOR pathway, p53 has been shown to regulate several transcriptional targets 
that modulate autophagy including DAPK-1, DRAM, and the target gene 
discussed in Chapter IV of this dissertation, ISG20L1.  The damage-regulated 
autophagy modulator (DRAM) is regulated by both p53 and p73; however was 
only found necessary for p53 induced autophagy that resulted in cell death 
(Crighton et al., 2007).  DRAM is lysosomal in location, induces markers of 
autophagy, and decreases cell survival but the mechanism by which it functions 
in autophagy has not been deciphered (Crighton et al., 2006).  
Dissertation research, described in Chapter IV, identified a novel p53 
family transcriptional target, ISG20L1, that is involved in genotoxic stress-induced 
autophagy (Eby et al.).  Using a newly generated antibody, we found that 
ISG20L1 levels increase in a p53- and TAp73-dependent manner after various 
forms of stress.  In addition to p53, the family members p63 and p73 can bind 
and directly regulate ISG20L1 expression.  Ectopic expression of ISG20L1 
decreased cell survival without induction of apoptosis as determined by flow 
cytometric analyses of sub-G1 DNA content or Annexin V staining.  Decreased 
clonogenic survival was partly rescued in an autophagy deficient cell line (ATG5-/- 
MEFs).   ISG20L1 was not involved in modulating 5-FU-mediated apoptosis, as 
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suppression of ISG20L1 in RKO cells did not alter the incidence or extent of 
apoptosis as measured by PARP and caspase-3 cleavage, sub-G1 content, or 
DNA laddering.  In contrast, siRNA knockdown of ISG20L1 decreased genotoxic 
stress-induced autophagy as measured by electron microscopy, as well as 
biochemical, and immunohistochemical analyses of the autophagy marker LC3-II.  
Thus, we identified ISG20L1 as a p53-family dependent, genotoxic stress-
induced modulator of autophagy.  
Further investigation will be necessary to determine the molecular 
mechanism of ISG20L1 in the modulation of autophagy. The family member 
IGS20L2 was recently shown to have exoribonuclease activity that is necessary 
for processing of the 12S rRNA into the mature 5.8S rRNA form (Coute et al., 
2008).  Preliminary data shows that IGS20L1 has 3ʼ-5ʼ exonuclease activity and 
is perinucleolar in localization, where rRNA maturation occurs (Lee et al., 2005).  
Other proteins involved in autophagy have been shown to play a role in nucleolar 
structure and processing of rRNA.  For example, p19ARF-null MEFs have a 
greater number of nucleoli and increased processing of immature rRNA 
compared to wild-type controls (Apicelli et al., 2008).  ARF, as described 
previously, can alter autophagy through p53-dependent and –independent 
mechanisms (Abida and Gu, 2008; Reef et al., 2006).  Additionally, the mTOR 
pathway that regulates autophagy, plays a large role in sensing nutrient 
availability and adjusting the synthesis of ribosomal components (Mayer and 
Grummt, 2006).  Thus we are interested in determining if ISG20L1 plays a role in 
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rRNA processing and if that mechanism alters autophagy.  Planned experiments 
would determine if knockdown of ISG20L1 alters processing of rRNA from the 
pre-rRNA to mature forms of rRNA (12s- 5.8s rRNA) using Northern methods or 
quantitative real-time PCR primers specific to the various cleavage forms. 
Future research to identify additional novel p53 family transcriptional 
targets involved in autophagy will be performed through our ongoing siRNA 
functional screen to characterize p53 target genes as discussed above.   Our 
laboratory and others have linked both p53 and p73 to autophagic processes 
(Eby et al.; Rosenbluth and Pietenpol, 2009).  The field of autophagy will need to 
further investigate what seems to be a contradictory role of p53 in both the 
suppression and activation of autophagy.  It could be hypothesized that these 
opposing roles of p53 are merely protein-level and context dependent as low 
levels of cytoplasmic p53 inhibits whereas nuclear, transcriptionally active p53 
activates autophagy.  This dual nature of p53 activity, as well as our laboratory 
findings that p73 is connected to the process of autophagy, invokes the question 
of the importance of autophagy as a p53 family tumor suppressive mechanism. 
Many questions remain in the field of autophagy regarding its ability to 
provide either oncogenic survival mechanisms or tumor suppressive methods in 
the process of tumorigenesis.  Evidence shows that under hypoxic conditions 
autophagy can promote tumor cell survival in vivo (Degenhardt et al., 2006).  
Cells that have developed defects in apoptosis have also been shown to live for 
weeks under conditions of nutrient withdrawal (Lum et al., 2005).  At the same 
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time, loss of autophagy gene expression occurs in human tumors and 
corresponding mouse models results in increased incidence of tumor formation, 
thus suggesting a strong tumor suppressive role for the process of autophagy.  
Monoallelic loss of Beclin1 is common in breast, ovarian, and prostate cancer as 
well as monoallelic deletions of UVRAG in colon cancer (Goi et al., 2003).  
Though the exact mechanism of tumor suppression is not known, autophagy has 
been suggested to suppress tumorigenesis through cell death mechanisms 
(Chen and Karantza-Wadsworth, 2009).  Various models for the role of 
autophagy in cell death exist and include autophagy as the primary inducer of cell 
death; autophagy induction prior to/ or at the time of apoptosis activation; and 
lastly that apoptotic induction actually inhibits autophagic mechanisms (Qian et 
al., 2007; Yu et al., 2006).  When both apoptosis and autophagy pathways are 
inhibited, cell death by necrosis was evident but activation of only one of these 
pathways decreased levels of necrosis (Kunchithapautham and Rohrer, 2007).  
Thus it remains unclear if autophagy alone is sufficient to complete cell death or if 
it requires cross-talk with other cell death machinery.   
Further characterization of the events leading to cell death requires 
additional in vitro experiments to shed light on the crosstalk between autophagy 
and apoptosis.  Measuring multiple markers of apoptosis and autophagy in a 
panel of cell lines after starvation or genotoxic stress-induced cell death will result 
in valuable data regarding the timing and communication between these two 
pathways.  Further, using siRNA or specific inhibitors to suppress either 
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autophagy or apoptosis will yield information on their individual roles as they 
contribute to cell death.  As more whole tumor genomes become available, it will 
be interesting to determine the frequency of alterations seen in the autophagic 
pathway.  In a recent seminar at Vanderbilt University, Dr. Beth Levine showed 
the first evidence of tumor regression in a mouse xenograft model using a small 
molecule that interrupts the Bcl-2 and Beclin1 complex allowing Beclin1 to induce 
autophagy.  Further investigation to discover if this small molecule causes 
autophagic induced pathways associated with cell death and of course 
determination if this small molecule can have a therapeutic benefit alone or in 
combination with other anticancer therapies in humans will need to be studied.  
To determine if autophagy is sufficient for cell death, novel methods for the 
assessment of autophagy will be critical in investigating the anticancer 
therapeutic potential of autophagy.   
 
Concluding Remarks 
As we identify p53-dependent target genes involved in a diversity of 
cellular processes, we continue to discover novel functions for p53 signaling.  
During the course of my dissertation research, I overlaid a number of genomic 
datasets and employed a mathematical ranking algorithm to identify a collection 
of putative p53 transcriptional targets.  I further characterized the role of one of 
these targets, ISG20L1, as a p53 family regulated target gene that modulates 
autophagy.  My research has laid the groundwork to apply high-throughput 
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siRNA technology in a way that has not been done before to simultaneously 
characterize these putative p53 target genes in multiple biological assays.   
Connections between the p53 family and autophagy are relatively new and 
ISG20L1 is one of only a handful of direct targets linking these pathways.  A 
pressing question in the fields of p53 and autophagy that requires further 
investigation is the role of autophagy in cell death.  To target autophagy for 
anticancer therapeutic purposes, it will be necessary to characterize the role of 
autophagy in tumor suppression and cell death.   With the completion of the 
siRNA functional screens, we hope to uncover and explore additional pathways 
and novel roles of p53 and its family members. 
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